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ZUSAMMENFASSUNG 
 Inzwischen ist bekannt, dass B-Lymphozyten phänotypisch und  funktional 
heterogen sind. Zusätzlich zu ihrer wesentlichen Funktion als Antikörper-
produzierende B-Zellen, dienen sie als Antigen-präsentierende Zellen und regulieren 
Immunreaktionen, unter anderem durch die Sekretion von  Cytokinen und 
Chemokinen. Obwohl bereits mehrere  Subpopulationen identifiziert worden sind, ist 
ein tieferes Verständnis für die Rolle der B-Zellen in der Pathophysiologie bei 
menschlichen Erkrankungen durch einen Mangel an exakt definierten B-Zell-
Subpopulationen behindert worden. In der vorliegenden Arbeit wurden vier B-Zell-
Subpopulationen mit sehr verschiedenen phänotypischen und funktionellen 
Eigenschaften durch eine umfassende phänotypische und funktionierende 
Charakterisierung mittels Expression von CD21 und CD86 definiert. Die CD21
pos
 
CD86
low
 B-Zell-Untergruppe zeigte einen naiven,  IgD
+
 IgM
+
 Phänotyp, der durch die 
fehlende Expression von Costimulatorischen- und Gedächtnis-Markern 
charakterisiert war. Zusätzlich wies sie ein niedriges Calcium- und Phosphorilierungs-
Niveau sowie eine starke Reaktion nach Stimulierung des B-Zellrezeptors auf. 
Darüber hinaus induzierte diese B-Zell-Untergruppe nur eine sehr langsame 
Aktivierung in autologen T-Zellen nach Cokultivierung. Die CD21
pos
 CD86
pos
 B-Zellen-
Untergruppe zeigte einen aktivierten, IgD
+
 IgM
+
 CD27
+
 Gedächtnis-Phänotyp und eine 
moderate Fähigkeit zur Induktion einer T-Zellreaktion. Die CD21
low
 Population, die in 
andere Untersuchungen in verschiedenen Erkrankungen als „ermüdet“ und wenig 
immunstimulatorisch beschrieben worden ist, konnte durch die unterschiedliche 
Expression von CD86 in zwei Untergruppen aufgeteilt werden. Die CD21
low
 CD86
pos
 B-
Zell-Untergruppe zeigte einen aktivierten, IgD
-
 IgM
-
 CD27
+
 Gedächtnis-Phänotyp, eine 
starke immunangregende Fähigkeit und eine beeinträchtigte Reaktion des B-
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Zellrezeptors. Diese konnte jedoch durch die synergistische Stimulierung mit dem 
CD40-Liganden wieder hergestellt werden. Im Gegensatz dazu war die CD21
low
 
CD86
neg
 B-Zellen-Untergruppe funktionell beeinträchtigt und wies Merkmale auf, die 
zu einem anergischen oder „ermüdeten“ Zustand passten. 
 In der vorliegenden Arbeit wurden bemerkenswerte Unterschiede in der 
Frequenz dieser B-Zell-Subpopulation in  verschiedenen Erkankungen fest gestellt. 
Dies lässt darauf schließen, dass die homöostatische Balance zwischen diesen 
Subpopulationen den funktionellen Zustand des gesamten B-Zell-Kompartiments 
definieren könnte. So hatten Patienten mit traumatischen Verletzungen 
beispielsweise einen erhöhten Prozentsatz an CD21
pos
 CD86
pos
 B-Zellen im Vergleich 
zu gesunden Spendern und Patienten mit rheumatischer Arthritis wiesen eine höhere 
Frequenz an CD21
pos
 CD86
pos
 und CD21
low
 CD86
pos
 B-Zellen auf. In Patienten mit 
Darmkrebs waren CD21
low
 CD86
pos
 B-Zellen im Tumorgewebe angereichert im 
Vergleich zu peripherem Blut von Darmkrebspatienten und gesunden Spendern. 
Zusammenfassend lässt sich fest halten, dass die verschiedenen B-Zell-Untergruppen 
unterschiedliche funktionelle Eigenschaften aufweisen, und dass sie eine Rolle in 
Autoimmun- und Krebserkankungen zu spielen scheinen. Dies legt den Schluss nahe, 
dass eine stärkere Fokussierung auf die spezifischen B-Zellen-Untergruppen eine viel 
versprechende therapeutische Strategie repräsentieren könnte. 
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ABSTRACT 
 It is now recognized that B lymphocytes are phenotypically and functionally 
heterogeneous. In addition to their essential role as antibody producing B cells, they 
serve as antigen-presenting cells, contribute to immunoregulation and represent an 
important source of cytokines and chemokines. Although several subpopulations 
have been identified, a deeper understanding of the role of B cells in the 
pathophysiology of human diseases has been hampered by the lack of well-defined 
functional B-cell subsets. In this study, a comprehensive phenotypic and functional 
characterization of B cells defined by expression of CD21 and CD86, revealed four B-
cell subpopulations with very distinct phenotypical and functional properties. CD21
pos
 
CD86
low
 B-cell subset had a naïve, non-switched phenotype characterized by the 
absence of expression of costimulatory and memory markers. Additionally, it was 
characterized by low basal calcium and phosphorylation levels and robust response 
after B-cell receptor stimulation. Furthermore, when cultivated with autologous T 
cells they induced very low stimulation. The CD21
pos
 CD86
pos
 B-cell subset had an 
activated, non-switched-memory phenotype and moderated immunostimulatory 
capacity. The CD21
low
 "exhausted" population described by others in several diseases 
could be partitioned in two subsets based on the expression of CD86. CD21
low
 
CD86
pos
 B-cell subset had an activated, class-switched-memory phenotype, potent 
immunostimulatory capacity and impaired B-cell receptor signaling that was restored 
by synergistic stimulation with CD40 ligand. On the other hand, CD21
low
 CD86
neg
 B-
cell subset was composed of functionally impaired B cells with features consistent of 
an anergic or exhausted state. 
 Since striking differences were detected in the frequency of these subsets in 
several medical conditions, it appears that the homeostatic balance between these 
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subpopulations could describe the functional state of the B-cell compartment. For 
instance, patients with traumatic fractures contained an increased percentage of 
CD21
pos
 CD86
pos
 B cells compared to healthy donors. Patients with active rheumatoid 
arthritis had a higher frequency of CD21
pos
 CD86
pos
 and CD21
low
 CD86
pos
 B cells. 
Patients with colorectal cancer revealed that CD21
low
 CD86
pos
 B cells were enriched 
within the tumor tissue compared to the peripheral blood of colorectal cancer 
patients and healthy controls. Taken together, the observation that the different B-
cell subsets display distinct functional features and that the different subsets are 
associated with immune-related diseases suggests that a more specific targeting of 
B-cell subsets could represent a promising therapeutic strategy. 
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1 INTRODUCTION 
 In addition to their recognized role in humoral immune response, B cells 
have several other functions less well understood. This research project seeks to 
contribute to a deeper understanding of the role that B cells play in antibody-
independent human responses. In order to get a better understanding of the 
alterations in B cell homeostasis and composition in physiologic as well as in the 
context of immune-related diseases, a detailed analysis of the B-cell compartments 
of healthy and patient samples was performed.  
1.1 Immune system 
 Humans and other higher-order animals are constantly exposed to a broad 
range of microorganisms that might threaten their survival. As a result, the immune 
system has evolved in a complex array of protective mechanisms, which recognize, 
control and eradicate such threats and preserve the homeostasis and normal 
function of the host. Using an interactive network of physical and chemical barriers, 
lymphoid organs, immune cells and secreted factors, the immune system is able to 
fight and discriminate whether these microbes are pathogenic or beneficial 
commensal organisms. More importantly, it can distinguish self from non-self. These 
functions become more obvious when the immune system is not functioning 
properly. As a consequence, immunocompromised patients are prone to 
development of severe infections and tumors while failure of tolerance mechanisms 
leads to allergic reactions and autoimmunity. 
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1.2 Innate and adaptive responses 
 The immune system is composed of two main branches referred to 
as innate and adaptive immunity. Although determined by the speed and specificity 
of the response, they are not mutually exclusive and act together (Parkin and Cohen 
2001). The innate response is the first line of host defense while the adaptive 
response is more prominent after a few days when B and T lymphocytes have 
undergone clonal expansion. Innate immunity includes common physical and 
chemical barriers to prevent the entry of harmful organisms. Moreover, cells such as 
neutrophils, monocytes and macrophages equipped with highly conserved 
recognition molecules identify the majority of pathogens, thereby ensuring a rapid 
and unspecific host reaction (Chaplin 2010).  
 It is not surprising that in order to defend the host against the overwhelming 
amount of microorganisms that are constantly changing and evolving, the immune 
system needs to evolve as well. The adaptive immune response is the answer to this 
challenge. The hallmark of adaptive immunity is that it relies mainly on the 
recognition of specific antigens by receptors expressed on B and T lymphocytes. 
Hence, adaptive immune responses are highly specific. In contrast to the germline-
encoded recognition receptors found on cells of the innate immune response, B and 
T lymphocytes express antigen-specific receptors, whose genes are assembled by 
somatic recombination of germline gene segments. The rearrangement of these 
elements results in a vast variety of intact T or B-cell receptor genes, each with a 
potentially unique specificity for a different antigen. This process ensures that at 
least few naïve B and T cells will have a high-affinity receptor to bind virtually any 
pathogenic antigen. Thus, the encounter with the specific antigen will lead to clonal 
expansion and generation of immunological memory for a rapid response in case of 
re-exposure (Bonilla and Oettgen 2010). 
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1.3 T lymphocytes 
 T cells develop from progenitor cells in the bone marrow that migrate to the 
thymus at early stage of their development. Naïve T lymphocytes that have not yet 
encountered their antigen traffic to secondary lymphoid tissues (lymph nodes, 
tonsils, mucosa-associated lymphoid tissue -MALT- and spleen). These areas provide 
the appropriate microenvironment in which lymphocytes and cells of the innate 
immune response, such as antigen-presenting cells (APCs) interact. Trafficking of 
lymphocytes through lymphoid organs is regulated by an array of adhesion molecules 
and chemokines, which brings cells in contact and increases the chances to recognize 
their specific antigen. Binding of antigen by the specific T cell in the context of 
costimulation by activated APCs leads to cell priming, activation and differentiation 
(Parkin and Cohen 2001).    
T lymphocytes bind antigen through the T cell antigen receptor (TCR). This 
type of receptor recognizes antigenic peptides that have been processed and 
presented in the context of major histocompatibility complex (MHC) molecules on 
the cell surface of APCs. After antigen recognition, T cells proliferate, migrate to 
antigenic sites and perform effector functions such as direct killing of antigen-
expressing cells (CD8
+ 
cytotoxic T cells) or release of cytokines to modulate the 
immune response (CD4
+  
helper T cells)  (Broere et al. 2011). 
1.3.1 CD8+ cytotoxic T Cells 
CD8
+
 cytotoxic T cells recognize 8-10 amino acid long peptides presented on 
the surface of their target cells in combination with self-MHC class I molecules (Klein 
and Sato 2000). Among their effector functions are the secretion of interferon (IFN)-γ 
and apoptosis-inducing molecules, such as perforin and granzyme B, and the up-
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regulation of Fas ligand. Moreover, specific antigen binding induces differentiation of 
memory T cells, which are faster and more efficient responders upon antigen re-
exposure (Weninger et al. 2002).  
1.3.2 CD4+ helper T Cells 
CD4
+
 T helper cells recognize 10-34 amino acid long peptides from 
exogenous proteins presented in combination with MHC class II molecules by APCs 
(Klein and Sato 2000). CD4
+
 T cells can differentiate into several functionally distinct 
subsets depending on the context of antigen encounter. According to the cytokine 
profile secreted, helper T cells can be divided broadly into type 1 (Th1), type 2 (Th2), 
Th17 and regulatory T cells (Tregs).  The cytokine environment plays a critical role in 
this lineage commitment process, for example interleukin-12 (IL-12) promotes Th1 
differentiation, whereas IL-4 promotes Th2 differentiation (O'Garra 1998). Th1 cells 
produce the proinflamatory cytokine IFN-γ and are responsible for regulating cellular 
immunity (Cohen et al. 2011). On the other hand, Th2 secrete IL-4, IL-5 and IL-13 
which favors humoral immune responses by B cells, while inhibiting Th1 cellular 
immune responses (Chang et al. 2009). 
A novel family of CD4
+ 
helper T cells was identified during the last years, 
which is essentially characterized by the production of IL-17 and was therefore 
named “Th17” (Cua et al. 2003, Harrington et al. 2005). Th17 cells exist both in mice 
and humans, but their phenotypic and functional characteristics, as well as the 
mechanisms responsible for their development in the two species, appear to be 
different (Romagnani 2008). In humans they have been found after polyclonal 
stimulation in peripheral blood and in gut from healthy individuals or patients with 
Crohn's disease (Acosta-Rodriguez et al. 2007, Annunziato et al. 2007).  
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Finally, Tregs are characterized by the constitutive expression of CD25 and the 
transcription factor forkhead box P3 (FoxP3) (Wing and Sakaguchi 2010). Tregs are 
key controllers of peripheral tolerance to self-antigens and alloantigens (Sakaguchi et 
al. 1995). 
1.4 B lymphocytes 
B lymphocytes are cells of the acquired immune response. They develop 
from progenitor cells in the bone marrow and remain there through their 
development. B cells recognize intact antigens through the B-cell receptor (BCR) that 
consists of an immunoglobulin (Ig) bound to the cell membrane (mIg). Activation of B 
cells is triggered by the binding of antigen to the BCR, thus initiating a cascade of 
signaling events that lead to antigen processing and presentation to T cells (Treanor 
2012).  
1.4.1 B cell origin and development 
 During early fetal development, Pre-B cells can be found in several tissues 
such as fetal liver (Gathings et al. 1977) and fetal omentum (Solvason and Kearney 
1992). However, after this stage and throughout life, B lymphopoiesis occurs only in 
the bone marrow (Figure 1).  
 B lineage cells develop from hematopoietic stem cells (HSCs) in fetal liver or 
adult bone marrow. Once HSCs undergo an asymmetrical division to generate one 
stem cell and one differentiating cell, it gives rise to progenitor cells that undertake 
lineage commitment to originate lymphoid or myeloid/erythroid progenitors. The 
common lymphoid progenitor (CLP) has the capacity to develop into T, B or natural 
killer (NK) cells but low or no capacity to generate cells of myeloid/erythroid lineage. 
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The model proposes that CLP can differentiate into two types of intermediate 
lymphoid progenitors: early-B cells or T/NK/dendritic cell (DC) tri-lineage cell (LeBien 
2000). Early-B cells that have not yet started BCR rearrangement are named 
progenitor B cells (pro-B cells) (Figure 1). During differentiation from CLP to pro-B 
cells recombination enzymes such as recombination-activating gene (RAG)-1, RAG-2 
and deoxynucleotidyl transferasa are activated to promote the ordered 
rearrangement of variable (V), diversity (D) and joining (J) gene segments to form the 
BCR (Ichii et al. 2014). 
 Pre-B cells arise from pro-B cells with the expression of the so-called pre-
BCR. The pre-BCR consists of the immunoglobulin heavy chain (µHC) pair with the 
surrogate light chain (SLC) components (VpreB and λ5) and the transmembrane 
proteins Igα and Igβ (also known as CD79a and CD79b) (Brouns et al. 1995). Pre-BCR 
expression is a pre-requisite for B cell development and also a signal for its own 
internalization and degradation (Burrows et al. 2002) as well as for inactivation of 
genes encoding the SLC components. Therefore, as cells proliferate, less pre-BCR 
complex can be formed on the surface. If a cell fails to generate a viable 
immunoglobulin light chain (IgLC) to associate to its µHC, it undergoes cell arrest and 
eventually death (Lam et al. 1997). Moreover, pre-BCR signaling induces 
rearrangements of the V and J light genes and allelic excision at µHC (Ichii et al. 
2014). At this stage IgLC assembles with the µHC resulting in an immunoglobulin of 
the IgM class, which is transported to the cell surface. Although BCR rearrangement 
is complete, cells at this stage are called immature B cells since they only express IgM 
and their ability to bind self-antigens is still to be tested (Figure 1).  
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Figure 1. B cell development and differentiation subsets 
Human B cell development in the bone marrow, differentiation subsets in peripheral 
blood and secondary lymphoid tissues: spleen and mucosa-associated lymphoid 
tissues (MALT). Modified from (Perez-Andres et al. 2010). 
 
 Immature B cells are particularly sensitive to tolerogenic signals, a feature 
that is lost after maturation and differentiation into B-cell subtypes with unique 
functions (Allman and Northrup 2007). In this respect, immature B cells undergo a 
receptor-mediated negative selection. During the process, only 20% of the cells 
survive and can emigrate from the bone marrow. Self-reactive B cells undergo 
negative selection through three known mechanisms: deletion, anergy and receptor 
editing in which auto-reactive cells undergo a further gene rearrangement to modify 
their receptors (Wang and Clark 2003). The fate of self-reactive immature B cells 
depends on several factors, including receptor affinity, IgM expression, stage of 
maturation and site of ligand encounter. It has been shown that binding of high-
avidity ligands leads to deletion (Erikson et al. 1991, Chen et al. 1994) while 
immature B cells that bind lower-avidity ligands become anergic (Goodnow et al. 
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2009). Level of IgM expression has also been related to how B cells respond to 
antigen. In vitro experiments done by Melamed et al, demonstrated that IgM
low
 
immature B cells undergo receptor editing after BCR stimulation. In contrast, BCR 
ligation on IgM
hi
 B cells induces apoptosis (Melamed et al. 1998). The 
microenvironment surrounding the place where immature B cells find the antigen is 
also affecting the outcome; while binding in the bone marrow induces receptor 
editing, ligation in the spleen induces deletion (Wang and Clark 2003). These 
mechanisms of tolerance diminish to a minimum the risk of reaction of B cells to 
tissues of the host organism.  
 As soon as the small proportion of cells that escape negative selection leave 
the bone marrow or fetal liver to populate peripheral blood and lymphoid tissues, B 
cells start to diversify the constant region of the membrane bound immunoglobulin 
(Figure 1). Via the process known as class switch recombination (CSR), maturing B 
cells start to express on the surface a second isotype with the same specificity, IgD. 
Isotype switching takes place through a mechanism of alternative splicing of a large 
primary messenger ribonucleic acid transcript containing both µ and δ constant 
region genes.  After splicing, the recombined VDJ gene contains the exon coding δ 
heavy chain segment to produce mIg of the IgD isotype (Geisberger et al. 2006). At 
this stage naïve B lymphocytes are characterized by their short-life span, their 
dominance during early phases of reconstitution of the peripheral B-cell pool and 
their susceptibility to undergo apoptosis rather than to proliferate in response to BCR 
ligation (Allman et al. 2001). 
 Naïve B cells recirculate through peripheral blood and enter lymph nodes, 
spleen and MALT (Figure 1). If they do not encounter antigen, they will continue 
recirculating until they die after a couple of days due to failed positive selection. 
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Those naïve B cells that bind their cognate antigen in the secondary lymphoid tissue 
will be primed and start the germinal center (GC) reaction in cooperation with CD4
+
 
and CD8
+ 
antigen-specific T cells (Figure 1) (Allen et al. 2007). In the GC, B cells are 
constantly migrating between the dark zone (centroblasts) and the light zone 
(centrocytes). In the dark zone, B cells undergo clonal expansion, CSR and somatic 
hypermutation (SHM) of variable heavy-chain region genes.  By the SHM process, 
non-templated point mutations are introduced in the variable region of rearranged 
immunoglobulin heavy and light chain genes. Then, in the light zone, they re-
encounter the antigen and undertake affinity maturation of the BCR (Allen et al. 
2007, LeBien and Tedder 2008). This results in the preferential outgrowth of B cells 
expressing an immunoglobulin that has high affinity for its cognate antigen (Odegard 
and Schatz 2006). 
 GC-B cells are characterized by up-regulation of CD10, CD38, CD95 and HLA-
DR and decreased expression of CD44 and bcl2 and heterogeneous expression of 
CD27 which differentiated them from naïve, memory B cells and plasmablasts (Allen 
et al. 2004, Allen et al. 2007). After undertaking several rounds of proliferation and 
affinity maturation, these cells become memory and pre-effector (plasmablasts) B 
cells (Allen et al. 2007). Quiescent memory B cells remain recirculating in peripheral 
blood or through tissues, where they can find antigen, while plasmablasts migrate to 
bone marrow or MALT to complete the differentiation and become antibody-
producing B cells (plasma cells -PCs-) (Figure 1) (Perez-Andres et al. 2010). 
1.4.2 Circulating peripheral blood B-cell subsets 
 B lymphocytes are phenotypically and functionally heterogeneous. During 
the past years, several subpopulations of B cells have been discovered. The use of 
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monoclonal antibodies (mAbs) and multicolor flow cytometry combined with 
functional assays has facilitated this work. The first attempt to classify human B cells 
was the introduction of the B mature (Bm) system (Liu and Arpin 1997). Tonsillar B 
cells were classified according to the surface expression of IgD and CD38. Five major 
subsets were reported: naïve B cells (IgD
pos 
CD38
neg)
 that can be further subdivided 
in Bm1 (CD23
neg
) and Bm2 (CD23
pos
) subsets, GC-B cells (IgD
neg 
CD38
pos
), which 
were separated by CD77 into centrocytes and centroblasts (Bm3 and Bm4) and the 
double negatives (IgD
neg 
CD38
neg
), which were described to be memory B cells 
(Bm5). This was the first classification of B cells. Although extremely useful, it is now 
clear that binary classification is not enough to discriminate between phenotypically 
different subpopulations that share the same surface profile.  
 In this way, IgM and/or CD27 are included nowadays to further categorize 
the populations (Weller et al. 2004). Therefore, new subgroups have been identified 
within the above subsets, i.e. Bm5 cells can be subdivided into memory B cells, which 
express CD27, and PCs, which do not (Youinou 2007). Moreover, later work 
demonstrated that CD77 does not discriminate centrocytes and centroblasts 
(Hogerkorp and Borrebaeck 2006). 
 Human naïve B cells comprise most of the peripheral blood B cells; they co-
express IgM and IgD and have unmutated Ig variable regions.  On the other hand, 
memory B cells consist of about 20 to 30% of all peripheral blood B cells and have 
undergone SHM, affinity maturation and about half also underwent CSR (Klein et al. 
1998, Tangye et al. 1998). Naïve and memory B cells also differ in terms of in vitro 
responsiveness to stimulation, mimicking the primary and secondary response in 
vivo. Therefore, memory B cells rapidly enter the cell cycle and undertake more 
rounds of division. A higher proportion of them become antibody-secreting PCs 
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(Fecteau and Neron 2003, Good et al. 2009). Both naïve and memory B cells 
recirculate in peripheral blood and lymphoid tissues. However, many of the memory 
B cells inhabit places of antigen draining such as the marginal zone of the spleen and 
the mucosa epithelium of the tonsils (Klein et al. 1998, Tangye and Tarlinton 2009). 
 Plasmablasts and PCs can be found in low frequencies in peripheral blood 
from healthy donors (Caraux et al. 2010). They are responsible for high affinity 
antibody secretion and humoral memory, providing a high quality defense when 
reencountering antigen. They represent 1-3% of total peripheral blood B cells and 
might be newly generated plasmablasts that are migrating from secondary lymphoid 
tissues to a niche in bone marrow or inflamed tissues (Brandtzaeg and Johansen 
2005). Higher frequency of PCs in peripheral blood has been associated with bacterial 
infection and systemic lupus erythematosus (SLE) (Ten Boekel et al. 2007). 
 Another minor subset of circulating immature B cells has been described in 
peripheral blood from healthy donors. In addition to expression of the B cell-specific 
marker CD19, this transitional B-cell subset can be identified using expression of the 
developmentally regulated markers CD24 and CD38. Transitional B cells make up 
around 2% of B cells, express high levels of both CD24 and CD38 (CD24
bright 
CD38
bright
), and co-express IgM and IgD and lack CD27 (Carsetti et al. 2004).  
Additionally, recently multiple regulatory B-cell subsets that suppresses 
cellular immune responses through the production of immunomodulatory cytokines 
have been identified. IL-10-producing B cells (B10 cells) are the most widely studied 
regulatory B cells (Yanaba et al. 2008, DiLillo et al. 2010, Mauri and Bosma 2012). 
These rare cells are named B10 cells to highlight that their regulatory function is 
mediated solely by its IL-10-dependent regulatory properties, and to distinguish 
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them from other B-cell subsets that regulate immune responses through different 
mechanisms (Ray et al. 2012).  
 In recent years, the development of multi-parameter flow cytometry 
coupled with improvements in the ability to purify minor cellular subsets using cell 
sorting has enabled the identification and characterization of novel B-cell subsets 
that can only be identified using a complex set of surface markers.   
1.4.3 B cells in health and disease 
 Immunity is coordinated by a complex network of cells that are continuously 
changing in response to the signals they receive. Therefore, there is a high degree of 
interdependency among the components, and any disruption in the tightly regulated 
process might result in a failure of the protective mechanisms of the immune system. 
The introduction of B cell-depleting agents has helped to uncovered the role of B 
cells in the pathogenesis of several immune-related diseases (Edwards et al. 2004, 
Looney et al. 2004, Sanz et al. 2007). Interestingly, depletion of B cells not only 
improved symptoms in diseases typically considered of B cell origin (such as SLE, 
idiopathic autoimmune thrombocytopenia, dermatomyositis and autoimmune 
blistering diseases) but also diseases in which B cells where not thought to play a 
major role (rheumatoid arthritis, multiple sclerosis and type 1 diabetes) (Edwards et 
al. 2004, Looney et al. 2004, Hauser et al. 2008, Xiu et al. 2008, Mei et al. 2012, 
Fuertes et al. 2013). Studies done in mice might explain the phenomenon, since they 
showed that mAb Rituximab (anti-CD20) therapy leads to B cell depletion by 
monocyte-mediated antibody-dependent cellular cytotoxicity (Uchida et al. 2004) 
and that amelioration of symptoms might be due to regulation of CD4
+
 T cell 
expansion, thus delaying and controlling the acute inflammatory phase that leads to 
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tissue damage (Bouaziz et al. 2007). Moreover, it might be that the therapeutic effect 
seen by this intervention is to a large extent related to the disturbance of the 
functional balance of B-cell subsets (Sanz and Lee 2010). 
 Malfunction in B-cell compartment influences development of 
immunodeficiencies, autoimmunity or hematologic malignancies. For instance, a 
typical immunodeficiency generated by disturbances in later stages of B cell 
development is common variable immunodeficiency (CVID). It is a disease that can be 
manifested at any time of life and is probably influenced by genetic or environmental 
factors. Patients exhibiting this disease have low serum immunoglobulin and are 
more susceptible to infections. Additionally, they have low levels of B cell memory, 
CSR and B cell activation (LeBien and Tedder 2008). It is important to stress that 
disruption in tolerance checkpoints in this disease results in a loosening of tightly-
controlled screening process for reactivity to self-antigens and predisposes to 
autoantibody production and autoimmunity. However, the role of B cells in the 
pathogenesis of autoimmune diseases is not restricted to autoantibody production 
but also contributes to autoantigen presentation to T cells and through 
proinflamatory cytokine production (Shlomchik 2008).  In the case of B cell-related 
cancer, disruption of differentiation at any stage of development (Figure 1) can lead 
to the expansion of a malignant counterpart of dominant subclones that ultimately 
derive in leukemia and lymphoma.   
1.4.4 Molecular architecture of B cells 
 It was not until 1980, with the use of mAbs that the molecular constitution 
of the B cell surface started to be identified. B cell molecules that have been 
characterized so far are associated with BCR signaling, development, function, 
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adhesion and communication with the extracellular environment (LeBien and Tedder 
2008).   
 B lymphocytes express on their surface several molecules that are shared 
with many other leukocyte types. For instance, B cells proliferate in response to 
bacterial deoxyribonucleic acid (DNA) due to signaling through Toll-like receptors 
(TLR), which are also known to be expressed by multiple leukocyte lineages (LeBien 
and Tedder 2008). As discussed earlier, CD38 and CD27 molecules are essential to 
define B-cell subsets although they are not B-cell lineage restricted (Jackson et al. 
2008). 
 On the other hand, several molecules are preferentially expressed by B cells. 
Among them are CD19, which can be found in virtually all B-lineage cells, CD20 that 
functions as a calcium (Ca
2+
) channel embedded in the membrane, CD21 (also known 
as complement receptor 2), CD22 and CD72 that negatively regulate BCR signaling, 
CD23 a low-affinity receptor for IgD, CD24 – a molecule with unknown function - and 
CD40 that serves as a survival factor for GC-B cells when binding to its ligand on T 
cells (CD40 Ligand -CD40L- also known as CD154) (LeBien and Tedder 2008). 
1.4.4.1 The complement receptor (CR) 2: CD21 
It is well known that in order to generate an appropriate immune response, 
B cells require not only BCR cross-linking but also additional signals through 
coreceptors such as CR1, CR2 and Fcɣ (FcɣRI, FcɣRII and FcɣRIII) receptors (Erdei et al. 
2009).   
 CR2, also known as CD21, is a glycoprotein receptor expressed by B cells, T 
cells and follicular DCs. On B cells it appears at the mature stage and disappears after 
PC differentiation. In humans, it is composed of 15 to 16 short consensus repeats, a 
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transmembrane domain and a short cytoplasmic tail and is generated from the CD21 
gene which encodes a single RNA transcript (Erdei et al. 2009). The interaction of 
CD21 with its ligands is known to require the first 2 consensus repeats (Lowell et al. 
1989, Szakonyi et al. 2001). CD21 binds C3 degradation products C3d, iC3b and C3b 
(Boackle et al. 1997). In addition it also binds CD23 (Aubry et al. 1992) and IFN-α 
(Asokan et al. 2006) and serves as entry receptor for Epstein-Barr virus (EBV) by 
binding pg350/220 glycoprotein on EBV (Nemerow et al. 1987).  CD21, as a receptor 
of complement fragments facilitates the cross-talk between the innate and adaptive 
branches of the immune response. 
 CD21 is expressed on the surface of B cells either as part of a trimolecular 
complex of CD21, CD19 and CD81 or associated with CR1 (CD35); very few reside 
alone (Tuveson et al. 1991, Grattone et al. 1999). As part of the B-cell coreceptor 
complex, cross-linking of CD21 and BCR by antigen-complex augments and 
potentiates activation through recruitment of CD19 and CD81, and helps to initiate 
downstream stimulatory events (Rickert 2005). In fact, C3d fragments deposit on 
antigen increases the immunogenicity by recruiting both proteins and inducing 
phosphorylation not only in CD19 but also in CD21 cytoplasmic tail (Dempsey et al. 
1996, Barrault and Knight 2004). In summary, there is substantial evidence that 
supports the in vivo significance of CD21 providing an important link between the 
innate and adaptive immune responses (Dempsey et al. 1996, Fearon and Carroll 
2000). 
 Most of circulating B lymphocytes expresses high levels of CD21. However, 
there is a small fraction of naïve and memory B cells with low levels of CD21 
expression. Although to date little information is known about the role of CD21
low
 B 
cells, in diseases such as CVID and human immunodeficiency virus (HIV) infection, the 
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frequency of this subset is increased (Moir et al. 2008, Rakhmanov et al. 2009).
  
1.4.5 B cell functions 
 During the past years, the old concept that B cells are exclusively committed 
to produce antibodies has been reconsidered. Nowadays, it is apparent that in 
addition to their essential role in humoral immunity, B cells accomplish many other 
tasks crucial for immune homeostasis (Figure 2). Of great importance is the 
requirement of B cells to initiate T cell immune responses. The first in vivo evidence 
for this assumption came from studies done by Ron et al., in which mice were 
depleted of B cells by administration of anti-µ antibodies from birth (µ-suppressed 
mice (µSM)) (Ron et al. 1981, Ron et al. 1983). After antigen inoculation with 
complete Freund's adjuvant, µSM had a severe impairment in CD4
+
 T cell activation. 
In addition, these mice were also more susceptible to bacterial and viral infection 
(Cerny et al. 1988, Cerny et al. 1988), had a reduced delayed-type hypersensitivity 
reaction to soluble antigens (Herrmann et al. 1988) and were resistant to diabetes by 
abrogating completely the development of insulitis and sialitis (done with µSM-
Nonobese diabetic mice) (Noorchashm et al. 1997). When mice were injected with B 
cells prior to antigenic challenge, the observed defects in µSM were largely overcome 
(Janeway et al. 1987, Ron and Sprent 1987, Noorchashm et al. 1997). All this 
evidence suggests that CD4
+
 T cell could not be efficiently primed in the absence of B 
cells and that B cells play a direct role as APCs. 
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Figure 2. B cell functions 
Selected examples of the multifunctional attributions of B cells and how they 
regulate immune homeostasis. Most of the functions of B cells are independent from 
antibody production. Modified from (LeBien and Tedder 2008).  
 
 APC function by B cells became controversial with the introduction of B-cell 
deficient mice generated by gene targeting either of the µ-chain or Ig heavy chain 
genes (Kitamura et al. 1991, Chen et al. 1993). Experiments done by independent 
groups with these B-cell deficient mice range from complete deficiency to almost 
normal T cell response (Epstein et al. 1995, Liu et al. 1995, Phillips et al. 1996, 
Macaulay et al. 1998). A more recent study using several B-cell deficient mice strains 
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generated by the same gene targeting technique demonstrated that in all but one 
strain (C57BL/6 background; which were used for most of the previous studies) T cell 
responses were impaired (Rivera et al. 2001). They showed that T cell priming of B-
cell deficient mice of C57BL/6 background were much more variable, explaining the 
controversial results.  
 In addition, by breeding chimeras it was possible to show that the congenital 
absence of B cells also plays a role during immune system development, which is 
evidenced by a diminished amount and diversity of thymocytes, defects within DC 
and T cell compartments, Peyer patch organogenesis and impaired chemokine 
expression by macrophages (LeBien and Tedder 2008). 
 Moreover, B cells are also important for regulation and maintenance of the 
immune system by cytokine secretion. Cytokine-producing B cells can be divided into 
regulatory B cells, which secrete IL-10  (B10 cells) or transforming growth factor 
(TGF)β-1 and effector B cells that produce IL-2, IL-4, tumor necrosis factor (TNF)α, IL-
6 or INFγ, IL-12 and TNFα (Lund 2008). By releasing cytokines, B cells can influence T 
cells, DCs, APC functions, regulate lymphoid tissue organogenesis and wound healing, 
modulate transplant rejection, tumor development and tumor immunity (LeBien and 
Tedder 2008). Moreover, the profile of cytokine released by effector B cells can 
influence the polarization of the T cell response (Harris et al. 2000). Additionally, 
cytokine production and antigen presentation by B cells have been associated to 
influence a range of diseases such as atherosclerosis, insulin resistance, HIV, graft-
versus-host disease, and allograft rejection (Moir and Fauci 2009, Shimabukuro-
Vornhagen et al. 2009, Ait-Oufella et al. 2010, Winer et al. 2011). 
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1.4.5.1 How B cells capture, process and present 
antigens?  
 In order to confer effective protection against the huge variety of 
pathogenic antigens that can face the immune system throughout the body, the 
response must be tightly harmonized. Therefore, antigenic interaction occurs mostly 
in defined sites (secondary lymphoid organs) such as lymph nodes and spleen. The 
lymphoid tissue possesses a highly compartmentalized microarchitecture that is 
essential for cellular interactions and initiation of optimal immune responses. In 
order to get activated and to exert APC function, B cells require two main signals. 
First, B cells recognize and capture the specific antigen by their BCR, which induces 
growth, proliferation, survival and expression of the costimulatory molecule CD86 on 
the B cells (Lenschow et al. 1994). Then, the antigen is degraded into peptide 
fragments that are loaded onto MHC class II molecules that are next presented on 
the cell surface to specific CD4
+
 T cells. Interaction with CD4
+
 T cells provides the 
second stimulatory signal mediated by CD40-CD40L binding and secretion of IL-4 by T 
cells (Figure 3) (Ranheim and Kipps 1993, Evans et al. 2000). T and B cell cooperation 
is required for proper B cell activation, GC formation, differentiation into high-affinity 
antibody-producing PC, generation of memory B cells (Yuseff et al. 2013) and proper 
APC function by up-regulation of the expression of MHC class I and II and 
costimulatory molecules CD80 and CD86 (Kennedy et al. 1994, Faassen et al. 1995).  
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Figure 3. Interaction between B and T lymphocytes 
Model for interaction between CD4
+
 helper T cell and B cell after antigen encounter. 
The antigen bound to the B-cell receptor (BCR) of the specific B cell is processed and 
the peptides of the processed antigen are presented in the context of MHC class II 
(MHC II) molecules to the helper CD4
+
 T cells via the T cell receptor (TCR). Optimal T-
cell activation takes place when the costimulatory molecules CD80 and CD86 interact 
with CD28, providing the necessary costimulation. The activated CD4
+
 helper T cells 
upregulate CD40L and secrete IL-4, which results in contact-dependent B-cell 
activation through CD40 and through IL-4 signaling. The functional end point after 
antigen encounter is differentiation of effector T and B cells. Modified from 
(Guttormsen et al. 1999). 
 
1.4.5.1.1 BCR internalization and signaling 
 Receptor endocytosis and initiation of signaling events required for B cell 
activation are induced by both soluble and membrane-bound antigens binding to 
BCR. Signaling through BCR and coreceptor starts with the recruitment and activation 
of tyrosine kinases. Critical for signaling is the transmembrane heterodimer Igα/β, 
which is associated noncovalently with the BCR coreceptor complex (Campbell et al. 
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1991). Upon antigen binding, mIg and Igα/β heterodimer, which contain highly 
conserved phosphorylation motifs (immunoreceptor tyrosine-based activation motif 
or ITAMs) are phosphorylated. Upon phosphorylation the BCR complex translocates 
to the glycolipid and cholesterol-rich membrane microdomains where proteins of the 
non-receptor protein tyrosine kinase Src family including Lyn, Fyn and Blk are 
constitutively present to initiate the down-stream cascade of activation signaling 
(Rickert 2005). Once phosphorylated, Igα/β ITAMs recruit and activate the tyrosine 
kinase SYK (Kurosaki et al. 1995). Subsequently, SYK and Src family kinases initiate 
separate but inter-related signaling pathways. While Src family kinases serve to 
phosphorylate nuclear factor (NF)-ƙB (Saijo et al. 2003), CD22 (Fujimoto et al. 1999) 
and BAM32 (Niiro et al. 2002), SYK phosphorylates BLNK (Fu et al. 1998), which in 
turns coordinates the assembly and activation of a receptor-retained signalosome 
containing phospholipase Cγ2 (PLCγ2), Vav, BTK, Nck, and Grb2 (Chiu et al. 2002).  
 Concurrent with signal initiation, the majority of BCR-antigen complexes are 
rapidly cleared from the cellular membrane. In fact, BCR-antigen engagement 
induces maturation of late endosomal and lysosomal compartments, into which BCR 
complexes are internalized and antigen is depredated by the acidification of the 
vesicles (Siemasko et al. 1998). Initial activation events in response to membrane-
bound antigen induce a biphasic spreading and contraction reaction on B cells. First, 
in the rapid spreading phase B cells extend lamellipodia across the follicular DC 
loaded with antigen increasing the amount of BCR-antigen interactions depending on 
the reorganization of the actin cytoskeleton. This dynamic structure, in addition to 
integrins such as leukocyte function antigen-1 (LFA-1), promotes the adhesion of B 
cells to APCs lowering the threshold for activation (Carrasco et al. 2004). 
Subsequently and more slowly, the B cell contracts cumulating antigen into a central 
cluster that acts as a platform for antigen internalization (Fleire et al. 2006). 
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Collectively the spreading and contraction responses determine how much antigen is 
acquired and presented by the B cell, and therefore determine the outcome of B cell 
activation (Depoil et al. 2008).   
 In addition, secretion of molecules of both endocytic and exocytic processes 
takes place in the immunological synapse. It is believed that proteases and 
hydrolases released in the vesicles are required to free the membrane-bound 
antigens from APCs and to start antigen degradation at the extracellular space 
(Yuseff et al. 2011). Some antigenic peptides released are directly loaded onto MHC 
class II molecules in the extracellular space probably at the same time that occurs in 
the main intracellular pathway. On the other hand, B cells also extract tethered 
antigen by trogocytosis, which involves the exchange of membrane fragments 
between cells (Aucher et al. 2008). 
 Synthesis of MHC class II and the costimulatorymolecules CD80 and CD86 
are also enhanced by BCR signaling (Reth and Wienands 1997, Zimmermann et al. 
1999). Internalization of the BCR is regulated by clathrin (Stoddart et al. 2002) and 
depends on the ubiquitylation of BCR-antigen complexes that occur downstream of 
SYK-dependent signaling (Katkere et al. 2012) providing evidence for the relationship 
between signaling and endocytic trafficking. Propagation of the signal continues 
within endocytic compartments, with further kinase phosphorylation that ultimately 
leads to transcription of genes required for B cell activation (Chaturvedi et al. 2011). 
1.4.5.2 CD40-CD40L interaction 
CD40 is a type 1 transmembrane protein member of the TNF-receptor 
family. It was first described in 1985 as a molecule constitutively expressed on B cells 
throughout development and differentiation (van Kooten and Banchereau 2000). 
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Furthermore, it is expressed by a variety of immune and non-immune cells including 
APCs such as macrophages, DCs and endothelial cells (Schonbeck et al. 2000). Its 
natural ligand, CD40L, is expressed mainly on activated CD4
+
 T cells (van Kooten and 
Banchereau 2000). It is a type 2 transmembrane protein of the TNF family of ligands 
and forms homotrimers on the cell membrane (Schonbeck et al. 2000).  Moreover, 
CD40L is also released in a soluble form (sCD40L) retaining its function and the 
trimeric structure of the membrane-bound protein (Mazzei et al. 1995). As described 
in section 1.4.5.1, interaction between CD40 and CD40L results in proliferation, 
differentiation and increased expression of surrogate molecules of APC function, 
which enhance efficacy of their antigen presentation capacity (Banchereau et al. 
1994, Yellin et al. 1994, von Bergwelt-Baildon et al. 2002). Antigen presentation in 
the context of MHC class II on the surface of APCs together with costimulation 
through receptors and ligand pairs, such as CD40-CD40L, enhances T cell activation 
and differentiation modulating the immune response (Figure 3) (Bretscher 1999). 
1.4.5.2.1 Signaling through CD40L 
Ligation of CD40 by its ligand induces the activation of several signaling 
pathways (Figure 4). The cytoplasmic signaling domain of CD40 lacks intrinsic 
catalytic activity, therefore upon activation relies on several proteins of the TNF 
receptor associated factor (TRAF) family that interact with different recognition motif 
in the cytoplasmic domains (Harnett 2004). Association of TRAF with CD40 leads to 
activation of MAPKs (mitogen activated protein kinases) ERK (extracellular signal 
regulated kinase), Jnk (c-Jun N-terminal kinase) and p38 and the canonical and 
noncanonical NF-ƙB pathways. ERK, p38 and Jnk are activated by a cascade of MAP 
kinases and result in the activation of transcription factors, among them Elk-1, ATF1 
and AP-1 (Fos/Jun), respectively (van Kooten and Banchereau 2000). Binding of 
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CD40L also induces phosphorylation of Janus Kinase 3 (JAK3) which produces a 
subsequent phosphorylation of STAT3 (signal transducer and activator of 
transcription) and STAT6 (Hanissian and Geha 1997, Karras et al. 1997). The JAK3 
pathway is relevant for activation of monocytes and DCs but seems to be of little 
importance for CD40-mediated B cell activation (Jabara et al. 1998, Revy et al. 1999, 
Saemann et al. 2002). In some systems, pathways such as PI3K (phosphoinositol 3 
kinase) and PLCγ2 have been shown to be induced upon CD40 signaling (Hanissian 
and Geha 1997, Harnett 2004). Additionally, there is some evidence that CD40 
stimulation activates protein Tyr kinases, such as Lyn, Fyn and SYK (Faris et al. 1994). 
  Downstream events of CD40 signaling include activation of canonical and 
noncanonical NF-ƙB and NF-ƙB-like transcription factors (Figure 4) (van Kooten and 
Banchereau 2000). The activation of the NF-ƙB pathway is mediated by the targeting 
of inhibitory proteins in a proteasome-dependent manner. In the case of the 
canonical NF-ƙB pathway, IƙBα is the inhibitor of p50/p65 and p50/c-Rel 
heterodimers, which retains them in the cytoplasm. Upon activation of the canonical 
NF-ƙB pathway, phosphorylation of IƙBα leads to its ubiquitination and subsequent 
degradation by the proteasome, which allows NF-ƙB translocation to the nucleus. On 
the other hand, in the noncanonical pathway, a protein called p100 is associated with 
RelB in the cytoplasm preventing the dimer’s translocation to the nucleus. Activation 
leads to phosphorylation and ubiquitin-proteasomal processing of p100 that then 
remains associated with as a p52- RelB dimer that can enter the nucleus and act as a 
transcription factor. CD40 triggering thus leads to the transcriptional activation of a 
variety of genes, including anti-apoptotic as well as cell cycle promoting genes 
(Figure 4) (van Kooten and Banchereau 2000, Harnett 2004). 
                                                                  Introduction                                                                                                                  
26 
 
 
Figure 4. CD40 signaling  
Upon CD40L binding and trimerization, CD40 associates with TRAF1, 2, 3, 5, 6 and 
JAK3 which leads to the activation of the MAPKs ERK, Jnk and p38, the canonical 
(p50/p65, p50/c-Rel) and the noncanonical (p52/RelB) NF-ƙB pathway, the PI3K and 
the PLCγ2 lipid-metabolizing enzymes and the JAK-STAT pathway. ERK, Jnk and p38 
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activate transcription factors in the nucleus that bind to DNA to activate gene 
transcription. Specific kinases (NIK and IKKs) activate the canonical and noncanonical 
NF-ƙB pathways by phosphorylation of inhibitors of NF-ƙB (p100, IƙB) marking them 
for processing and degradation, respectively, by the ubiquitin-proteasomal pathway. 
P105 is processed constitutively to p50 by the proteasome. NF-ƙB heterodimers 
then translocate to the nucleus and act as transcription factors for specific genes. 
CD40 also mediates phosphorylation of Lyn by unknown mechanisms. TRAF (TNF 
receptor associated factor), JAK (Janus kinase), NIK (nuclear ƙ B inducing kinase), IKK 
(IƙB kinase), IƙBα (Inhibitor of ƙ B α), Ub (Ubiquitin), P (phosphorylation), PI3K 
(Phosphoinositol 3 kinase), PLCγ2 (Phospholipase Cγ2), STAT (signal transducer and 
activator of transcription), Jnk (c-Jun N-terminal kinase), ERK (extracellular signal 
regulated kinase). Modified from (van Kooten and Banchereau 2000, Harnett 2004). 
 
1.4.6 Generation of CD40-activated B cells in vitro  
 Since antigen presentation by B cells has been shown to be essential for 
optimal induction of T cell immunity (section 1.4.5) a system for generation of B cells 
with antigen-presenting capacities was urgently needed. Banchereau et al. were the 
first to report in 1991 the “CD40-system”. They established a protocol to generate 
long term human B cell lines by continuous stimulation with CD40L and IL-4 
(Banchereau et al. 1991, Banchereau and Rousset 1991). BCR stimulation combined 
with CD40-mediated signaling is the most potent activation stimulus for B 
lymphocytes. After CD40-activation B cells up-regulate the expression of key 
molecules involved in antigen presentation such as MHC class II or the costimulatory 
molecules CD80 and CD86. Schultze et al., described CD40-activated B cells (CD40B 
cells) to be an alternative source of extremely efficient APCs (Schultze et al. 1997). 
Since then, several ex vivo strategies based on interaction between CD40 and its 
ligand have been developed to generate highly potent APCs either by soluble or 
membrane-bound CD40L-expressing cell line (Wennhold et al. 2013). CD40B cells can 
be loaded to generate antigen-specific APCs by peptide, protein or tumor lysates 
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pulsing, by transfection with DNA or RNA or by transduction with viral vectors (Kondo 
et al. 2002, von Bergwelt-Baildon et al. 2002, Lapointe et al. 2003, Coughlin et al. 
2004, Ahmadi et al. 2008).  
 Phenotypically CD40B cells are characterized by high and stable expression 
during long-term culture of MHC class I and II molecules, costimulatory molecules 
such as CD80 and CD86 and adhesion molecules CD58 and CD54.  More importantly, 
CD40B cells are able to induce antigen-specific T cell responses in vitro and in vivo by 
either priming naïve or expanding antigen-experienced memory T cells. In addition, 
expression levels of molecules and APC function of CD40B cells are comparable to 
CD40L-stimulated mature monocyte-derived DCs (Schultze et al. 1997, von Bergwelt-
Baildon et al. 2002). Phenotypically and based on their pattern of gene expression 
they resemble germinal center B cells (Kondo et al. 2002, Wennhold et al. 2013). 
 As described in section 1.4.5, in order to initiate an immune response, APCs 
need to encounter T cells, a process regulated by chemokine gradients in the T cell 
areas of secondary lymphoid organs (von Andrian and Mempel 2003). CD40B cells 
induce chemotaxis of T cells by expression of chemokines CCL17 (TARC), CCL5 
(RANTES), CCL22 (MDC) and CXCL10 (IP-10) as evidenced by increasing migration of 
both CD4
+
 and CD8
+
 T cells in transwell experiments with CD40B supernatant. In 
addition, CD40B home to secondary lymphoid organs as confirmed by the expression 
of CD62L, CCR7/CXCR4 and LFA-1 (Klein-González et al. 2010). 
 Although, the activity of CD40B cells as APC and their capacity to induce 
immunity in vivo is still being investigated, it is clear that they are potent APCs. 
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1.4.6.1 DCs vs. CD40B cells as antigen presenting cells
  
 Since DCs are highly specialized in antigen capture, processing, presentation 
and activation of T cells, they are frequently used in cellular immunotherapy as 
source of APCs (Cella et al. 1997). Moreover, they have been used in several 
antitumor vaccine clinical trials (Lapteva et al. 2007). Nevertheless, despite the 
encouraging results and their significant immunostimulatory capacity, several 
challenges have been identified in the context of clinical application. On the one 
hand, they are very rare in peripheral blood and their expansion ex vivo is expensive 
and laborious (Ardeshna et al. 2000). On the other hand, with the use of standard 
protocols the generation of homogeneous population of DCs is very difficult. This 
procedure usually gives rise to subpopulations that may act tolerogenic (Hackstein et 
al. 2001) or DCs that lack L-selectine, an important molecule for homing to the lymph 
nodes (Barratt-Boyes et al. 2000). Furthermore, reports from our group and others 
have shown that DC purity in clinical trials rarely exceeds 50% of the vaccine 
preparation (Draube et al. 2011). 
 An alternative source of highly efficient APCs are B cells activated through 
CD40 and IL-4 signaling. Their use in clinical settings and research can overcome the 
difficulties found in generation and cultivation of DCs. CD40B cells become highly 
proliferative upon activation, they can be easily expanded from small amounts of 
peripheral blood B cells and its possible to obtain highly pure preparations of CD40B 
cells with potent antigen presentation capacity in vitro (Schultze et al. 1997, von 
Bergwelt-Baildon et al. 2002, Garcia-Marquez et al. 2014). 
                                                                  Introduction                                                                                                                  
30 
 
1.5 CD21low CD86pos cells: an in vivo counterpart to in vitro 
generated CD40B cells? 
 There is a lack of phenotypically well-defined B-cell subset with antigen-
presenting capacity that helps to elucidate the exact role that B cells play in these 
processes in humans. Recently a B-cell subset with phenotypic characteristics 
resembling CD40B cells was identified (Shimabukuro-Vornhagen et al. in review). 
 It was demonstrated using a transcriptomic approach that after in vitro 
CD40 activation several genes involved in B cell differentiation and activation were 
down-regulated. Specially, immunoreceptors such as complement and Fc receptors, 
which are known to participate in BCR signaling and antigen uptake (Figure 5A). 
Additionally, long-term activation with CD40L was accompanied by the up-regulation 
of the costimulatory molecule CD86 but more importantly the down-regulation of 
the complement receptor 2, CD21 (Figure 5B). Therefore, a feature of long-term 
CD40 activated B cells (after 21 days of culture) was the down-regulation of CD21 
and up-regulation of CD86 (Figure 5C). The long-term CD40B cells were shown to 
induce strong proliferation of allogeneic T cells compared to non-activated B cells 
(Figure 5D and E). These data were kindly provided by Rieke Fischer. 
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Figure 5. CD21 down-regulation and CD86 up-regulation as features of long-term 
activated B cells 
Purified Human B cells were activated by culture in the presence of CD40L-expressing 
NIH3T3 fibroblast and pro-inflamatory cytokine IL-4. (A) Heat map visualizing 
expression of immunoreceptors involved in antigen uptake in resting B cells (B cells) 
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and CD40-activated B cells (CD40B). Only genes differentially expressed are depicted. 
Relative expression values are normalized across each row and color coded. Genes 
with high levels of expression are shown in red, those with low or no expression in 
blue (n=4). (B) Up-regulation of the costimulatorymolecule CD86 as well as down-
regulation of CD21 are the result of prolonged B cell activation. Data are represented 
as the percentage of change in mean fluorescence intensity to day 0 of culture of the 
indicated molecule over time, with standard deviation bars (MF ± SD) gated on the 
CD19
+ 
CD20
+
 B-cell population (n=14). (C) Change in CD21 and CD86 expression 
during the course of the CD40 culture. Shown are representative plots from one 
donor. (D,E) T cell proliferation in response to a mixed lymphocyte reaction (MLR) 
with either 21-days CD40-activated or non-activated B cells. (D) FACS plots from one 
representative donor. T cells that proliferate in response to B cell activation were 
identified as CD25
+ 
CFSE
Low
 T cells. (E) The decrease in CD21 expression was 
associated with an increase in immunostimulatory capacity of CD40B cells as shown 
by increase proliferation of allogeneic CFSE-labeled T cells cultured with CD40B cells 
at day 21. Bar charts represent the mean ± SD of 2 independent experiments with 
samples from different donors. 
 
 Since reduced expression of CD21 and increased expression of CD86 turned 
out to be a characteristic phenotype for long term-activated CD40B cells with strong 
immunostimulatory capacity, these markers were used to search for a similar 
phenotype in humans. Based on the expression of the markers CD21 and CD86, 
human peripheral blood B cells were divided into four B-cell subsets (Figure 6A). The 
majority of B cells were CD21
pos
 CD86
neg
. The CD21
low
 B cells could also be further 
separated into a CD86
neg
 and CD86
pos 
subpopulations (Figure 6B). Interestingly, a 
spanning-tree progression analysis of density-normalized events (SPADE), which 
allows the visualization of multidimensional flow cytometric data without prior 
knowledge, also identified the presence of the distinct B-cell subsets (Figure 6C). 
Importantly, flow cytometric analysis of peripheral blood of a patient with CVID 
revealed that expanded CD21
low
 B subset in patients with CVID corresponded to 
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CD21
low
 CD86
neg
 B-cell subsets (Figure 6D) (Shimabukuro-Vornhagen et al. in 
review). These data were kindly provided by Rieke Fischer. 
 
Figure 6. CD21 and CD86 defined four B-cell subsets in peripheral blood from 
healthy donors. 
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(A) Flow cytometric analysis of human peripheral blood B cells. Shown is a 
representative dot plot from a healthy donor showing the distribution of four B-cell 
subsets according to the expression of CD21 and CD86. Populations are color-coded 
(CD21
pos
 CD86
low
 in blue, CD21
pos
 CD86
pos
 in orange, CD21
low
 CD86
pos
 in red and 
CD21
low
 CD86
neg
 in violet). This color-code for the populations will be use throughout 
the rest of the document. (B) Scatter plot showing the frequency of the four B cells 
subsets in healthy human individuals (n=10). Bars denote the mean ± SD. (C) SPADE 
tree colored by the two markers CD21 and CD86. The size of each circle in the tree 
indicates the relative frequency of cells that fall within boundaries of surface marker 
expression that define each node. Node color is scaled to the median intensity of 
expression of the indicated markers. (D) FACS plot from peripheral blood of a CVID 
patient compared to a healthy control. 
 
1.6 Aim of the study  
 Since four B-cell subsets were identified according to the expression of the 
markers CD21 and CD86, this study aimed to extensively characterize phenotypically 
and functionally these human B-cell populations. Based on the fact that CD40B cells 
are potent antigen-presenting cells and that CD21
low 
CD86
pos
 B-cell subset 
resembled CD40B cells in terms of CD21 and CD86 expression, it was hypothesized 
that they could have an immunostimulatory phenotype and function. In order to test 
this hypothesis, a novel cell-free CD40L system was established to produce potent 
antigen-presenting B cells in vitro. Activated B cells generated with this system were 
used to compare the phenotype and the function to CD21
low 
CD86
pos
 B cells to study 
whether they represent the physiologic counterpart to in vitro generated CD40B cells 
in humans. Finally, B-cell subsets were analyzed in several clinically relevant human 
diseases to determine whether and how the four B-cell subsets were disturbed. 
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Chemicals 
For preparation of buffers and solutions, chemicals of analytical purity were used 
exclusively.  
Table 1: Chemicals 
Name  Manufacturer  
2-Propanol Roth 
Bovine Serum Albumin (BSA)  Sigma Adrich 
Calcium chloride (CaCl2) Merck 
CFSE: 5-(and-6)-carboxyfluoresceindiacetate, succinimidyl ester 
Dimethyl sulfoxide (DMSO)   
Invitrogen 
Sigma Aldrich Ethanol 70 % Roth 
Ethylenediaminetetraacetic acid (EDTA) 
Hydrogen Peroxide (H2O2) 30 % (w/w) 
Sigma Aldrich 
Sigma Aldrich ygr mycin B 
Paraformaldehyde (PFA) 
Sodium chloride 
PanreacAppliChem 
Sigma Aldrich 
Sigma Aldrich 
Trypsin-EDTA Life Technologies  
2.1.2 Reagents 
Table 2: Reagents 
Name Composition/Manufacturer 
10 x Phosphate buffered saline (PBS) Life Technologies 
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AB-Human serum Life technologies 
AIM-V medium Life Technologies 
CpG-ODN 2006 human TLR-9 ligand 
Ciclosporin A 
Miltenyi Biotech 
Sigma Aldrich DMEM medium 
Dynabeads® Human T-Activator CD3/CD28 
Life Technologies 
Gibco Fetal Bovine Serum (FBS)  Lonza 
Fluo-3 acetoxymethyl esters Molecular Probes 
Fura-Red acetoxymethyl esters  Molecular Probes 
G418 Biochrom 
Goat F(ab´)2 anti-human IgM (µ chain specific) Southern Biotech 
IMDM medium Life Technologies 
LEAF Purified anti-human CD3 clone OKT3 BioLegend 
Pacific blue succinimidyl ester Molecular Probes 
Pacific orange succinimidyl ester Molecular Probes 
Pancoll human, density 1.077 g/mL  
Penicillin/ Streptomycin 
Pluronic F-127 
recombinant human (rh) Insulin 
rh Interleukin-2 (2000 U/mL) 
rh Interleukin-4 (50 U/mg) 
rh Transferrin (25 mg/mL) 
RPMI 1640 medium (with or without Phenol Red) 
PAN-Biotech  
Life Technologies 
Molecular Probes 
Novo Nordisk  
Immunotools 
Sigma Aldrich 
Sigma Aldrich 
Life Technologies 
Sodium Orthovanadate Sigma Aldrich 
Trypan Blue Stain 0.4 % Life technology 
Tumor Dissociation Enzyme DCS-Innovative 
  
2.1.3 Buffers and solutions 
Table 3: Buffers and solutions 
Name Composition/Manufacturer 
Cell fix (1 x) BD Biosciences 
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Cell wash BD Biosciences 
Cell staining buffer 1 x PBS 
2 % FBS 
0.1 % Sodium Azide 
pH 7.4 
PBS (1 x) 1 L 10 x PBS 
9 L Ampuwa EasySep Purification Buffer 1 x PBS 
2 % FBS 
1 mM EDTA 
MACs Separation Buffer 1 x PBS 
0.5 % BSA 
2 mM EDTA 
HEPES Buffer (1 M) Biochrom 
FACS sheath fluid BD Biosciences 
Freezing medium FBS 
10 % DMSO Perm Buffer III BD Bioscience 
PhosphoFlow wash buffer 1 x PBS 
1 % FBS Pervanadate Solution (10 
mM) 
20 µL 100 mM Sodium Orthovanadate solution 
23 µL 30 % H2O2 
157 µL RPMI + 2 % FBS 
Mix and incubate 15 minutes 
Pervanadate Solution (500 
µM) 
Dilution 1:20 Pervanadate solution (10 mM) in RPMI + 
2 % FBS 
2.1.4 Cell culture media 
Table 4: NIH3T3 Standard medium 
Medium Supplementation (Final Concentration) 
DMEM-Ham´s / F12  
 L-Glutamine 365 µg/mL 
 FBS 10 % 
 HEPES 10 mM 
 Penicillin/Streptomycin 10 % 
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Table 5: Human CD40B wash medium 
Medium Supplementation (Final Concentration) 
IMDM  
 L-Glutamine 584 µg/mL 
 HEPES 25 mM 
 Penicillin/Streptomycin 10 % 
 
Table 6: Human CD40B culture medium 
Medium Supplementation (Final Concentration) 
IMDM  
 L-Glutamine 584 µg/mL 
 HEPES 25 mM 
 AB-Human serum 10 % 
 rh Transferrin 50 µg/mL 
 rh Insulin 5 µg/mL 
 Penicillin/Streptomycin 10 % 
 
Table 7: Calcium flux medium 
Medium Supplementation (Final Concentration) 
RPMI without Red Phenol  
 FBS 2.5 % 
 Penicillin/Streptomycin 10 % 
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2.1.5 Kits 
Table 8: Kits 
Name Manufacturer 
CD19 MicroBeads®, human Miltenyi Biotec 
CD20 microbeads®, human Miltenyi Biotec 
EasySep Human T cell enrichment kit Stemcell Technologies  
Human CD40-Ligand multimer kit Miltenyi Biotec 
LEGENDScreen™ Human Cell Screening (PE) Kit BioLegend 
2.1.6 Cell lines 
 The adherent CD40L-transfected NIH3T3 fibroblasts were used. These 
feeder cells were kindly provided by Dr. Gordon Freeman (DFCI, Boston, USA). 
Table 9: Tools and instrumentation 
Devices Manufacturer 
Cell sorter Aria III    Becton-Dickenson 
EOS 350D digital camera Canon 
Freezing Chamber Nalgene NUNC 
Gallios Flow Cytometer Beckman Coulter 
Gentle MACS Dissociator Miltenyi Biotec 
HeraCell 150i CO2 Incubator Thermo Scientific 
Heraeus Megafuge 16R  Thermo Scientific 
Neubauer Counting Chamber OptikLabor 
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Purple EasySep Magnet StemCell Technologies 
Reax Top mixer Heidolph 
Refrigerated microfufe Sigma 1-14K Sigma Laborzentrifugen 
Televal 31 microscope Zeiss 
Water bath WNB14 Set Memmert 
  
Table 10: Consumables 
Name Manufacturer 
5 mL flow cytometric tubes Sarstedt 
5 mL (12 x 75 mm) polystyrene tubes Falcon 
6-, 12-, 48- well culture dish  (flat bottom) NUNC 
15 mL Falcon tube Sarstedt 
15 mL (17 x 100 mm) polystyrene tubes Falcon 
50 mL Falcon tube Sarstedt 
70 μm nylon cell strainers Greiner 
96-well culture dish (round- and v-bottom) NUNC 
C-Tubes Miltenyi Biotec 
Cryo tubes 1.0, 1.8 mL Sarstedt 
Pre-Separation filter 30 µm Miltenyi Biotec 
LD Columns Miltenyi Biotec 
LS Columns Miltenyi Biotec 
MS Columns Miltenyi Biotec 
Pipette tip 5, 10, 25 mL Sarstedt 
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Pipette tip 10, 200, 1000 μL Sarstedt 
Syringe 50 mL B. Braun Melsungen AG 
Syringe filter 0.22 μm Millex-GV 
Tissue culture flask 75, 175 cm
2
 Sarstedt 
 
Table 11: Software 
Name Manufacturer 
FlowJo Software TreeStar 
GraphPad Prism GraphPad Prism Software 
Kaluza Software Beckman Coulter 
  
2.2 Methods   
2.2.1 Blood samples 
Buffy coat preparations were obtained from healthy donors at the blood 
bank of the Universitätsklinikum Köln, Germany. Peripheral blood and bone marrow 
from healthy adult volunteers, rheumatoid arthritis, EBV, CVID, cancer and trauma 
patients have also been used in this study. Peripheral blood from cancer patients was 
obtained immediately prior to surgery. Tonsils from non-malignant tonsillectomies 
were included as well. Donors gave their consent and all the experiments were 
approved by our institutional ethical board.   
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Human peripheral blood mononuclear cells (PBMCs) were isolated using 
Pancoll density-gradient centrifugation. A maximum of 16 mL whole blood treated 
with EDTA were diluted with an equal volume of PBS. In another tube, 15 mL of 
Pancoll solution were carefully covered with a layer of diluted blood, without mixing 
the phases. After a centrifugation step (1080 g, 20 minutes) at room temperature 
(RT) the PBMCs were harvested from the white blood cells layer between the plasma 
sample layer and the Pancoll. The separated PBMCs were washed twice in PBS to 
remove remaining platelets, serum and Pancoll. 
2.2.2 Cell subset enrichment 
2.2.2.1 B cell purification 
B cells were enriched using positive immunomagnetic selection with human 
CD19 or CD20 MicroBeads and used fresh at the time of the experiment. The 
procedure was performed according to the manufacturer’s protocol (Miltenyi 
Biotech, Germany) with minor modifications. PBMCs were resuspended in 40 µL 
MACS buffer per 1 x 10
7 
cells and magnetically labeled with 10 µL CD19 (or CD20) 
MicroBeads per 1 x 10
7 
cells (15 minutes, at RT). Labeled cells were filtered into a 
MACS Column placed on the magnetic field of the MACS separator. CD19
+ 
(or CD20
+
) 
B cells were retained in the magnetic column while unlabeled cells were eluted. 
Positively selected B cells were washed out from the column, counted and B cell 
purity was determined. B cell purification by MACs MicroBeads yielded in purities of 
>96 % CD20
+
 CD19
+ 
B cells as determined by flow cytometric analysis. 
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2.2.2.2 B-cell subset isolation by fluorescence activated 
cell sorting (FACS) 
PBMCs were isolated from healthy donors buffy coats and allowed to rest 
overnight at 4 °C. After 12 hours, B cells were isolated with CD19
+ 
MicroBeads and 
stained with CD20, CD21 and CD86. CD3 was used to exclude T cells that could 
remain after B cell enrichment. B cell purity was confirmed after separation. B-cell 
subsets were separated according to the expression of CD21 and CD86 with the flow 
cytometry-based cell sorter Aria III (Becton-Dickenson) at the Central Cell Sorting 
Facility located in the CMMC building at the University Hospital of Cologne, Germany. 
During isolation and throughout the process cells were kept under sterile conditions 
and on ice.  
 
2.2.2.3 CD3+ T cell isolation 
T cells were purified by negative selection using the human T cell 
enrichment kit, according to the protocol of the manufacturer (Stem Cell 
Technologies, Canada). Briefly, cells were resuspended in EasySep medium at a 
concentration of 5 x 10
7
 cells/mL. Cells were incubated for 10 minutes at RT with 
EasySep Human T Cell Enrichment Cocktail and for additional 5 minutes with EasySep 
D Magnetic Particles at 50 μL/mL cells. Afterwards, the tube with cells was placed 
into the EasySep purple magnet for 5 minutes. After the incubation time was ended, 
the desired cell fraction was poured off into a new tube by inverting the magnet. The 
negative selected cell suspension was washed and counted. Enrichment of CD3
+
 T 
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cells by EasySep Human T cell Enrichment Kit yielded in purities of >96 % CD3
+
 T cells 
as determined by flow cytometric analysis. 
2.2.2.4 Cell isolation from human tumor tissue 
 Tissue was obtained from colorectal cancer patients. Fresh unfixed tissue 
from primary tumor lesions, which were not required for pathological analyzes, were 
collected and processed immediately after surgical resection (within 12 hours). The 
samples were provided by an experienced pathologist from the pathology 
department of the University Hospital of Cologne, Germany, who made sure that the 
obtained samples were indeed tumor tissue. The fresh tumor tissue was manually 
minced using a scalpel and then transferred into single cells suspensions using a 
gentle MACS Dissociator (Miltenyi Biotec). For enzymatic disruption, Tumor 
Dissociation Enzyme was used and single cell suspensions were obtained by 
sequential dissociation and incubation according to the company’s instructions. 
Finally, the cells were filtered through 70 μm nylon cell strainers, washed, counted 
and stained for flow cytometric analysis. 
2.2.3 Cell culture 
If not described differently, all cells were incubated at 37 °C in a humidified 
atmosphere with 5 % CO2. Cell culture was performed at sterile conditions under a 
safety cabinet with sterile solutions, glass and plastic ware. All centrifugation steps in 
cell culture were performed in a Heraeus Megafuge 16R (Thermo Scientific). 
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2.2.3.1 Counting of cells – Trypan Blue exclusion test 
For counting, a Neubauer chamber was used. An aliquot of the cell 
suspension was diluted (10 x) in Trypan Blue Stain 0.4 % to differentiate viable from 
non-viable cells. Using a light optical microscope with 20 fold magnification, bright, 
unstained cells were counted viable. Four corner quadrants of the Neubauer 
chamber were counted completely. The average cell number per quadrant was 
multiplied by 10
4
, resulting in the number of cells per 1 mL. The total cell number 
was calculated by including the dilution factor and the total volume of the cell 
suspension. 
2.2.3.2 Cryopreservation and thawing of cells 
To preserve living cells intact without causing major damage, cells were 
resuspended in a cold freezing medium at a density of 5-10 x 10
6
 cells/mL. Cryotubes 
were placed into a pre-cooled freezing chamber containing isopropanol for slow 
freezing. The freezing chamber was stored at -80 °C for 24 hours and then cryotubes 
were transferred to liquid nitrogen for long-term storage. 
For thawing, cryotubes were rapidly removed from nitrogen and put into a 
water bath at 37 °C until a small ice clump was left in the tube. The cell suspension 
was then resuspended in an excess of medium and centrifuged at 200 g for 5 
minutes. 
2.2.3.3 Trypsinization of adherent cells 
Adherent cells were washed once with 10 mL of 1 x PBS and 4 mL of Trypsin-
EDTA was added for detachment of the cells. Cells were incubated at 37 °C for 5-10 
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minutes, followed by addition of 5 mL medium containing FBS to stop the 
trypsinization process. Finally, cells were harvested, washed twice (200 g, 5 minutes) 
and resuspended in standard medium. 
2.2.3.4 Culture of NIH3T3/tCD40L cell line 
The NIH3T3/tCD40L cell line is an adherent murine fibroblast cell line 
expressing the human CD40L that was kindly provided by Dr. Gordon Freeman (DFCI, 
Boston, MA, USA).  Cell passaging was performed twice a week. Briefly, adherent 
NIH3T3/tCD40L cells were first trypsinized (section 2.2.3.3), then resuspended in 10 
mL NIH3T3 standard Medium (Table 4) in order to determine cell number (section 
2.2.3.1). To maintain the NIH3T3/tCD40L culture, 1.5 x 10
6
 cells were seeded in 10 
mL NIH3T3 standard medium supplemented with G-418 (0.7 mg/mL) in a 75 cm
2
 
culture flask and incubated at 37 °C. To ensure stable expression of CD40L on the 
transfected cells, flow cytometry was weekly performed using a PE-conjugated anti-
human CD154 antibody. 
2.2.3.5 Generation of CD40-activated B cells with 
NIH3T3/tCD40L cell line 
CD40-activated B cells were generated as described previously (von 
Bergwelt-Baildon et al. 2006, Liebig et al. 2009). Briefly, purified CD19
+
 B cells were 
cultured on murine NIH3T3/tCD40L feeder cells at a seeding density of 1 x 10
6
 
cells/mL. NIH3T3/tCD40L feeder cells were previously irradiated at 26 Gy. B cells 
were cultured in human CD40B medium (Table 6) with 50 U/mL of recombinant 
human IL-4 (ImmunoTools, Germany) freshly added. Cultures were maintained until 
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day 21. Expansion of B cells was measured by counting cells twice a week using 
Neubauer chamber and trypan blue exclusion (section 2.2.3.1). Following CD40L 
activation CD40B cells were cryopreserved in liquid nitrogen (section 2.2.3.2) for later 
use in autologous and allogeneic mixed lymphocyte reaction (MLR) (section 2.2.8).   
2.2.3.6 Generation of CD40-activated B cells with soluble 
CD40L 
 CD19
+
 B cells were cultivated with multimer human recombinant CD40L 
(rCD40L) as described previously (Garcia-Marquez et al. 2014). Briefly, B cells were 
seeded (1 x 10
6
 cells/mL) in CD40B medium supplemented with freshly added 
recombinant human IL-4 (50 U/mL) and human CD40L Multimer kit from Miltenyi 
Biotec according to manufacturer’s instructions (2 μg/mL rCD40L + 10 μg/mL 
crosslinking antibody, pre-incubated at room temperature for 30 minutes). On day 5, 
half of the medium was removed and replaced with medium supplemented with 
fresh rCD40L and IL-4. At day 7 and day 10 the expanding CD40B cells were counted, 
cell density was adjusted and cells were cultured for further expansion. Cultures 
were maintained until day 14. Growth of B cells was measured by counting cells on 
day 7, 10 and 14 using Neubauer chamber and trypan blue exclusion (section 
2.2.3.1). 
2.2.3.7 Assessment of cell morphology by microscopy 
 To assess the morphology of B cells during culture, a representative spot 
was chosen and photographed by using an inverted phase Zeiss Televal 31 
microscope fitted with a Canon EOS 350D digital camera. 
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2.2.4 Phenotype analysis of single cells by FACS 
Acquisition and enumeration of cells were performed using a Gallios Flow 
Cytometer (Beckman Coulter, Pasadena, USA). Single-cell analyzes were performed 
with the FlowJo software (Tree Star, Ashland, USA) or the Kaluza software (Beckman 
Coulter, Pasadena, USA). All washing steps were performed with cell wash in a 
Heraeus Megafuge 16R (Thermo Scientific) at 270 g for 5 minutes at RT. 
2.2.5 Surface staining with monoclonal antibodies 
To evaluate frequency and phenotype of each B-cell population, PBMCs 
were stained with antibodies for flow cytometric analyzes. Staining procedure was 
done with 0.1 – 1 x 10
6
 cells in 100 µl cell wash with antibody cocktails (1 
µL/antibody, up to 10-parameters) for 20 minutes at 4 °C. Afterwards, cells were 
washed and resuspended in 150 - 300 µl cell wash depending on the cell number. 
Monoclonal antibodies used for phenotype analysis, conjugates and companies are 
listed in table 12. Isotype control antibodies and/or unstained samples 
were used when appropriate. 
For examining Ki-67 expression in each B-cell population, PBMCs were first 
permeabilized with cold ethanol 70 % at -20 °C for 1 hour. Subsequently, cells 
were stained with anti-Ki-67 PerCp Cy 5.5 antibody. At the end of the 
incubation, cells were washed, resuspended in cell staining buffer and 
analyzed by flow cytometry. 
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2.2.6 Human monoclonal antibodies used for frequency 
and conventional phenotype analysis 
Table 12: Anti-Human antibodies 
Antigen [clone] Isotype Labeling Manufacturer 
CD3 Mouse IgG1,Ƙ 
Mouse IgG1,Ƙ 
ECD 
PE-e Fluor 610 
Beckman Coulter 
eBioscience   I ,  C7 Beckma  Coulter 
CD4 Mouse IgG1,Ƙ  
Mouse IgG1,Ƙ 
Pacific Blue 
PE 
BioLegend 
Beckman Coulter CD8 s  I ,  erCP/Cy5.5 ioLege d 
CD19 Mouse IgG1,Ƙ 
Mouse IgG1,Ƙ 
Alexa Fluor 780 
Alexa Fluor 700 
BioLegend 
BioLegend CD20 se Ig 2b, Ƙ Pacific Blue i Lege  
CD21 Mouse IgG1,Ƙ  APC BioLegend 
CD25 Mouse IgG1,Ƙ PE Cy 7 BioLegend 
 Mouse IgG1,Ƙ PE Beckman Coulter 
CD27 Mouse IgG1,Ƙ PC 7 Beckman Coulter 
CD32 Mouse IgG2b,Ƙ FITC BD Biosciences  
CD43 Mouse IgG1,Ƙ APC ImmunoTools 
CD45 Mouse IgG1,Ƙ Pacific Orange Beckman Coulter 
CD62L Mouse IgG1,Ƙ ECD Beckman Coulter 
CD80 Mouse IgG1,Ƙ FITC BioLegend 
CD83 Mouse IgG1,Ƙ PE Caltag 
CD86 Mouse IgG1,Ƙ PE BioLegend 
HLA-DR Mouse IgG1,Ƙ PerCP Cy5.5 eBioscience 
IgD Mouse IgG1,Ƙ FITC BD Biosciences 
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IgM Mouse IgG1,Ƙ PE BD Biosciences 
IgG Mouse IgG1,Ƙ FITC BD Biosciences 
Ki-67 Mouse IgG1,Ƙ PerCP Cy5.5 BioLegend 
 
 The LEGENDScreen Human Cell Screening (PE) Kit was used to further 
phenotypically characterize the B-cell subsets. The kit containing 332 PE-conjugated 
monoclonal antibodies to cell surface markers as well as 10 mouse, rat, or Armenian 
hamster Ig isotype controls was used according to manufactures' instructions to 
screen expression of all known CD molecules among the B-cell subsets. Briefly, CD19
+ 
B cells were isolated (section 2.2.2.1), stained with CD20, CD21 and CD86 and 0.8 × 
10
5 
cells were added to each well after the lyophilized antibodies were reconstituted. 
Cells were then stained for 20 minutes at 4 °C, washed, and fixed with Fixation 
Buffer. Cells were then washed, resuspended in 160 μL of Cell Staining Buffer, and 
analyzed by flow cytometry. 
2.2.7 Gating strategy for flow cytometry analysis 
 Flow cytometry generated data were analyzed as follows. Briefly forward 
and sideward scatter plots were used to gate on lymphocytes and doublets were 
excluded using time of flight (TOF). Following gating on CD45
+
 events, the B cells 
were identified by the expression of CD19 and CD20 (Figure 7). Then, B cells were 
further subdivided into four subpopulations according to their expression of CD21 
and CD86.   
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Figure 7. Gating strategy for flow cytometry analysis 
In this gating sample, cells were first gated according to the size (-SS- side scatter vs. -
FS- forward scatter). On top of each plot and in brackets appears the immediate 
parent population. At the sides of each plot are shown the antibodies and their 
respective fluorochromes.   (1) The lymphocyte gate (Lymph) is further analyzed to 
exclude doublets and non-lymphocyte cells with the singlets (2) and CD45 (3) gates, 
respectively. (4) Within the CD45
+ 
lymphocyte population, B cells are gated based on 
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the expression of CD19 and CD20 and then further subdivided (5) by the expression 
of CD21 and CD86. Phenotypic and functional characterization of the B-cell subsets 
described in this work was based on this gating strategy. 
 
2.2.8 Autologous and allogeneic MLR for T cell 
proliferation analysis 
 B cells activated with CD40L after 1, 3, 7, 14 and 21 days, cryopreserved and 
or B-cell subsets sorted from CD19
+
 B cells based on the expression of CD86 and 
CD21 which were used as stimulators (1–10 x 10
4
 cells/well) with negatively selected 
autologous or allogeneic T cells (10 x 10
4
 cells/well) in a final volume of 200 µL in 96-
well round-bottom plates, at 37 °C in a 5 % CO2 humidified atmosphere. Stimulator B 
cells were always irradiated (26 Gy) before mixing with T cells. For the autologous 
MLR, T cells were also stimulated with IL-2 (25 U/mL) and OKT3 (10 µg/mL). As 
positive control T cells were cultivated in the presence of magnetic CD3
+
 CD28
+
 
Beads.  
 Prior to co-culture, purified T cells were labeled with the fluorescent 
proliferation marker CFSE.  Briefly, T cells were resuspended in PBS with 5 % FBS and 
stained by the addition of 5 μM of CFSE pre-diluted in PBS. Cells were mixed and 
stained uniformly by agitating the tube constantly for 5 minutes in the dark. After 
extensive washing to remove excess CFSE, CFSE-labeled T cells were plated in 
triplicates in RPMI 1640 media supplemented with 10 % FBS, 1 % HEPES, 2 mmol/L L-
glutamine with 10% Penicillin/Streptomycin. After 5 days of co-culture (7 days 
autologous MLR), cells were harvested and stained with the following antibodies for 
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flow cytometry analysis: CD25 PE, CD62L ECD, CD3 PC7, CD8 PerCp Cy5.5, CD4 Pacific 
Blue and CD19 Alexa Fluor700 (Table 12). 
2.2.9 Analysis of Ca2+ mobilization. 
 For analysis of intracellular Ca
2+
 flux, MACS-purified human CD20
+
 B cells 
were loaded for 60 minutes at 37 °C with 12 µM Fura-Red acetoxymethyl esters (AM) 
and 6 µM Fluo-3 AM (Molecular Probes, Eugene, USA) in the presence of 0.2 % 
Pluronic F-127 (Molecular Probes, Eugene, USA) in calcium flux medium (Table 7) 
with cells being resuspended every 20 minutes. Afterwards, cells were washed with 
and resuspended in calcium flux medium. The loaded cells were subsequently 
stained with antibodies against CD19, CD21, and CD86. After basal Ca
2+
 
concentrations were monitored, cells were stimulated with various reagents. The 
fluorescence Fluo-3/Fura-Red ratio was recorded for the next minutes on a Gallios 
flow cytometer (Beckman Coulter). The analysis of the kinetics was performed using 
FlowJo software. 
Table 13: Dyes used for the detection of free intracellular Ca
2+
 by flow cytometry 
Dye Excitation (λmax) Emission (λmax) Excitation laser 
Fluo-3 503 nm 526 nm (green) Argon at 488 nm 
Fura red 472 nm 637 nm (red) Argon at 488 nm 
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2.2.10 Multiplexed phospho-specific flow cytometric 
profiling (PhosphoFlow) 
2.2.10.1 Stimulants used in PhosphoFlow experiments 
 Cells were stimulated either with 10 µg/mL of soluble CD40L (Miltenyi 
Biotech, Germany), 10 µg/mL goat F(ab´)2 anti-human IgM (µ chain specific) or a 
combination of CD40L and IgM (5 µg/mL each). In some cases, to amplified 
downstream signaling, B cells were exposed immediately before stimulation to 3.3 
mM H2O2. This dose was identified by Irish et al, as one that stimulates little signaling 
on its own in primary human B cells but effectively inactivates the catalytic cysteine 
of phosphatases so that subsequent protein tyrosine phosphatase (PTPs)-regulated 
signals proceed unchecked (Irish et al. 2006). In some experiments, B cells were 
stimulated with a final concentration of 45 µM of Pervanadate solution for 5 minutes 
without further stimulation neither with CD40L nor IgM. 1 % FBS in PBS was used as 
negative stimulation control. 
2.2.10.2 Cell stimulation 
 After isolation, CD19
+
 B cells were allowed to rest for 2 hours at 37 °C, 5 % 
CO2 in AIM-V medium. Thereupon, cells were washed and resuspended in ice cold 
flow wash buffer (PBS + 1 % FBS) and transferred to 2 mL eppendorf tubes (500 µL 
containing 5 x 10
6 cells). Before stimulation, samples were plated in the thermo 
block pre-heated at 37 °C for 3 minutes. Stimulant aliquots (10 µL) were added to B 
cells and incubated for different time periods. After stimulation, cells were fixed with 
500 µL of 4 % PFA (10 minutes) and washed twice with flow wash buffer. 
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2.2.10.3 Staining and fluorescent-cell barcoding 
 For fluorescent-cell barcoding pacific blue- and pacific orange- succinimidyl 
ester (Molecular Probes, Eugene, USA) were prepared at different concentrations 
(Pacific blue 8-100 pg/µL; Pacific Orange 25-250 pg/µL); 5 µL of each dilution was 
added per well in V-bottom 96-well plate. Fixed cells were washed and resuspended 
in 100 µL PBS. Thereupon, 90-95 µL of fixed cells were plated on top of the 
corresponding barcoding dilution, mixed vigorously and allowed to stain for 20 
minutes in the dark at RT. After staining, plate was washed twice with flow wash 
buffer and barcoded cells were collected together in a 15 mL Falcon tube on ice. Cells 
were washed again and permeabilized with pre-cooled perm buffer III (BD 
Bioscience, USA) for 30 minutes at -80 °C. Permeabilized cells were rehydrated and 
washed twice with flow wash buffer. Samples were then stained with antibodies 
cocktails in flow wash buffer for 30 minutes at RT. Antibodies in the cocktails 
included cell surface markers CD20-Alexa Fluor 488 (clone H1(FB1), BD Phosflow), 
CD86-PE (clone IT2.2, BioLegend) and CD21-PerCpCy5.5 (clone Bu32, BioLegend). 
Phospho-antibodies were all in Alexa Fluor 647 (BD Phosflow) and included pZAP70 
(Y319)/pSYK (Y352), BTK (pY551)&Itk (pY511), pERK (T202/Y204) and NFƙB-p65 
(pS529). Cells were washed with and resuspended in flow wash buffer before been 
acquired on a Gallios flow cytometer. 
2.2.11 Statistics 
 Significant differences were calculated by the Student’s t -test for 
paired/unpaired data depending on the group. When multiple groups were 
compared one-way ANOVA with Tukey´s multiple comparisons test was used 
according to the case. When groups with more than one variable to analyze were 
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compared the two-way ANOVA with Tukey´s or Sidak´s multiple comparisons test 
according to each case were used. When data was compared to a normalized 
population, the one sample t test was used. P-values of less than 0.05 were 
considered statistically significant and marked with asterisks: * p ≤ 0.05, ** p ≤ 0.01, 
*** p ≤ 0.001, **** p ≤ 0.0001. Mean values and standard deviations (SD) were used 
unless otherwise stated. 
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3 RESULTS 
3.1 Generation of highly proliferative antigen presenting B cells 
was achieved by activation via soluble as well as membrane 
bound CD40L 
 As described earlier (section 1.4.6), potent antigen-presenting B cells can be 
generated via CD40 activation. Most common available systems include triggering 
CD40 with agonist CD40-monoclonal antibodies or the usage of CD40L membrane 
fractions, as well as CD40L-expressing feeder cells such as Schneider 2 cells (Yoon et 
al. 2005), NIH3T3/tCD40L cells (Schultze et al. 1995) and 293-CD40L-sCD40L human 
cell line (Ivanov et al. 2005). The main problem with antibody mediated CD40 
stimulation is the weak proliferative response of B cells. The level of B cell activation 
and proliferation seems to depend on the degree of CD40 crosslinking (Fanslow et al. 
1994, Morris et al. 1999, Haswell et al. 2001). Accordingly,  the most efficient way to 
induce B-cell proliferation thus far is through cell membrane-bound CD40L (Ivanov et 
al. 2005, Yoon et al. 2005). However, the cell-standing systems introduce xenogeneic 
contaminations that might influence experimental results. Moreover, this has also 
prevented the translation of the system to the clinic settings. Consequently, a 
soluble, cell-free CD40L system was established as an effective culture method for 
generation and expansion of CD40B cells in vitro through the use of a multimerized 
form of human recombinant CD40 ligand (rCD40L). 
 The rCD40L system was compared in terms of proliferation, induction of 
activation markers and immunostimulatory capacity to the well-established and 
effective membrane-bound CD40L system with NIH3T3 cells. 
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 Purified human CD19
+
 B cells were activated by culturing them together 
with either NIH3T3/tCD40L feeder cells or rCD40L in the presence of IL-4 for 14 days. 
As expected, flow cytometric analysis revealed that stimulation of human B cells via 
rCD40L induced up-regulation of costimulatory molecules CD80, CD86, HLA-DR and 
the adhesion molecule CD62L (Figure 8A). Expression levels were always comparable 
to that observed with NIH3T3/tCD40L cells. The purity of cultures on day 14 was 
above 96-98 % of CD19
+ 
CD20
+
 B cells (data not shown). Signaling through CD40L also 
induced expression of adhesion molecules resulting in the formation of B cell clusters 
via homotypic adhesion (Figure 8B), which is an important step of B cell activation via 
CD40 (Klaus et al. 1994). Larger clusters were observed with the rCD40L but in the 
NHI3T3/CD40L system clusters were more rounded and evenly shaped.   
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Figure 8. Ligation of B cells by CD40L induced activation and homotypic cluster 
formation 
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CD19
+
 B cells from 4 healthy donors were cultured with either soluble rCD40L or 
NIH3T3/tCD40L feeder cells in the presence of IL-4 for 14 days. B cells were analyzed 
by flow cytometry. (A) Culture of B cells with rCD40L (blue line) as well as 
NIH3T3/tCD40L (black line) up-regulated the expression of costimulatory molecules 
and the adhesion molecule CD62L. Data is represented as the percentage increase of 
the mean fluorescence intensity (MFI) with standard deviation bars (SD) of each 
molecule over time. (B) Light microscopy pictures of a representative donor at day 7, 
10 and 14 of culture with either rCD40L or NIH3T3/tCD40L showing clustering of B 
cells. Photos were taken with 5X magnification and size bars are shown (scale bar in 
all pictures is 100 μm). No significant differences between the two stimuli were 
detected by two-way ANOVA with Tukey´s multiple comparisons test.   
 
 Extensive expansion of human B cells was achieved by stimulation with both 
rCD40L and NIH3T3/tCD40L. Proliferation rates remained constant until the end of 
the culture and no differences between the two systems were found. Growth was 
determined by manually counting cells with trypan blue during the culture as well as 
with the fluorescent proliferation marker CFSE (Figure 9A and B, respectively). Only a 
very low expansion rate was observed when rCD40L was not incubated with the 
cross-linking antibody indicating that cross-linking of the soluble rCD40L is necessary 
in order to induce proliferation of B cells. As shown in Figure 9B, proliferation of the 
entire population in response to rCD40L + IL-4 (light grey histograms) was also 
confirmed by CFSE dilution. Control B cells were cultivated only with IL-4 and as 
expected no proliferation was observed (dark grey histograms). 
                                                                                                                 Results 
63 
 
 
Figure 9. B cell proliferation in response to CD40 ligation 
Proliferation of B cells cultivated with CD40L was measured at day 7, 10 and 14. (A) 
Proliferation of CD19
+
 B cells cultured with rCD40L, NIH3T3/tCD40L and rCD40L 
without additional treatment with cross-linking antibody determined by trypan blue 
exclusion. (n=11, mean ± SEM -standard error of the mean-). (B) Histograms of one 
representative donor showing CFSE dilution as a consequence of B cell division 
induced by rCD40L (light grey) compared to B cells stimulated only with IL-4 (dark 
grey). 
 
 As demonstrated by means of an MLR, both CD40L systems were able to 
generate highly potent APCs that induced activation as determined by CD25 
expression and strong proliferation of allogeneic T cells (Figure 10A). Only at a lower 
B to T cell ratio (1:10) rCD40L-B cells were more efficient inducing T cell proliferation 
than NIH3T3/tCD40L-B cells (Figure 10B). Non-activated B cells from the same donors 
were used as negative controls. As positive controls, T cells were cultivated in the 
presence of activating Dynabeads CD3
+
 CD28
+
 (data not shown).  
Thus, an effective soluble system was established, in which contamination with 
xenogeneic components was avoided. Data from these experiments was used to 
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compare functional and phenotypic characteristics to the CD21
low
 CD86
pos
 peripheral 
blood B-cell subset. The soluble, cell-free rCD40L system proved to be an efficient 
method to generate highly potent and proliferating antigen-presenting cells. 
Moreover, can be used as an in vitro system to study antigen presentation in human 
B cells and to establish similarities and differences with peripheral blood CD21
low 
CD86
pos B lymphocytes.   
 
Figure 10. CD40 activated B cells induced strong proliferation of allogeneic T cells 
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T cells were cocultured either with CD40Bcells (rCD40L-B cells or NIH3T3/tCD40L-B 
cells) or non-activated B cells at B cell-to-T cell ratios of 1:1 and 1:10. Proliferation of 
CD3
+ 
T cells was determined after 5 days by means of CFSE dilution. (A) 
Representative FACS-plots from one representative donor show differences in T cell 
activation and proliferation when T cells were cultured with non-activated or CD40 
activated B cells (ratio 1:1). Activated, proliferating cells were identified by 
expression of the activation marker CD25 and low CFSE fluorescence. (B) Figure 
displays the mean and SD bars of the proliferating CD25
+ 
CFSE
low 
T cells from three 
healthy donors. Significant differences were calculated by one-way ANOVA with 
Tukey´s multiple comparisons test. Asterisks represent: * p ≤ 0.05, ** p ≤ 0.01, *** p 
≤ 0.001. 
 
3.2 Similar distribution of B-cell subsets was found in human 
peripheral blood, as well as in primary and secondary 
lymphoid organs 
As described in section 1.5 (Figure 5), a novel B-cell subset with similar 
phenotypic characteristics to CD40B cells, namely reduced expression of CD21 and 
increased expression of CD86 was previously identified in peripheral blood from 
healthy donors. In order to determine site-dependent differences in primary and 
secondary lymphoid organs, samples from non-malignant tonsillectomies and bone 
marrow from healthy donors were collected and analyzed to search for a similar 
phenotype. Therefore, by flow cytometry CD19
+ 
CD20
+
 B cells were classified based 
on the expression of CD21 and CD86. Bone marrow and tonsils were compared to 
peripheral blood from a cohort of 41 healthy volunteers. The vast majority of 
peripheral blood B cells were CD21
pos 
CD86
neg
 B cells (83.97 % ± 7.677).  Double 
positive B cells CD21
pos 
CD86
pos
 constituted 1.57 % ± 0.9564 of the total B cells while 
the CD21
low
 B cells, further separated into CD86
pos
 and CD86
neg 
subpopulations 
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made up of 1.193 % ± 0.9720 and 13.27 % ± 7.012, respectively (Figure 11A). A 
similar distribution of the subsets was found in bone marrow (Figure 11B) and tonsils 
(Figure 11C). Interestingly, the proportion of activated, CD21
pos 
CD86
pos 
and CD21
low 
CD86
pos 
B cells was increased in the tonsils (25.52 % ± 12.26 and 2.553 % ± 2.279, 
respectively). This could be explained by the fact that these donors underwent 
tonsillectomies due to inflammation of the tonsils. 
 
Figure 11. Frequency of B-cell subsets in human peripheral blood, bone marrow 
and lymphoid tissue. 
Lymphocytes from peripheral blood and bone marrow from 41 and 7 healthy 
volunteers respectively, and 13 tonsils from non-malignant tonsillectomies were 
analyzed by flow cytometry. Shown are scatter plots representing the frequency of 
CD19
+
 CD20
+ 
B-cell subsets according to the expression of CD21 and CD86 in (A) 
peripheral blood, (B) bone marrow and (C) tonsils. Bars denote the mean ± SD. 
Percentages of cells for each subset are calculated out of the total CD19
+ 
CD20
+
 B 
cells. 
 
 To study inter-individual differences in the frequency of the four B-cell 
subsets, the healthy cohort was divided by gender and age. The age of the subjects 
varied from 18 to 89 years, with an average of 44 years. The CD21
low
 CD86
pos
 B-cell 
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population showed a clear gender difference (Figure 12A). After matching subjects by 
age it became obvious that in individuals below age 50 women had significantly 
higher percentage of CD21
low
 CD86
pos
 B cells than men (1.412 % ± 0.8015 against 
0.7030 % ± 0.3412, respectively) (p=0.0334, n=10). However, in people aged 50 and 
older the percentage of CD21
low
 CD86
pos
 B cells was not significantly different 
(p=0.0927, n=7). This could indicate that hormonal differences might affect the 
homeostasis of this B-cell subset and that the gender difference disappears after 
women reach menopause. Despite the gender-dependent differences, the 
composition of the B-lymphocyte population in peripheral blood did not show age-
dependent changes (Figure 12B). 
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Figure 12. Individual variation in the frequency of B-cell subsets 
Gender and age differences were evaluated in peripheral blood from healthy 
volunteers. CD19
+
 CD20
+
 B cells were divided into four B-cell subsets according to the 
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expression of CD21 and CD86. (A) Frequency of CD21
low
 CD86
pos
 B cells was analyzed 
comparing age-matched men and women younger than 50 years (n=10) and older 
(n=7). Significance was calculated with a paired t test and exact p values are given in 
the text. (B) Changes on the composition of the four B-cell subsets as a function of 
age. The lines represent the linear regression curve. The corresponding coefficient of 
determination (r
2
) and significance values (p) for each population are indicated in 
each plot. 
 
3.3 Phenotypic characterization of the four B-cell subsets 
 More detailed phenotypic analysis of cell size, proliferative status, stage of 
maturation and expression of activation molecules and chemokine receptors 
revealed characteristic differences between the four B-cell subsets.  
3.3.1 CD21low CD86pos B cells were significantly larger than 
the other subsets 
The cell size of the four subsets differed significantly (Figure 13). Consistent 
with the assumption that they represent activated B cells, both CD21
pos
 CD86
pos
 and 
CD21
low
 CD86
pos
 B cells were significantly larger than CD86
neg 
subsets. The largest 
cells were CD21
low
 CD86
pos 
B cells with an MFI of the forward scatter signal (FSS) of 
314.5 ± 6.491, followed by CD21
pos
 CD86
pos 
with 278.2 ± 7.707, the double negatives 
CD21
low
 CD86
neg
 with 257 ± 9.328 and the smaller were CD21
pos
 CD86
neg
 B cells with 
249.9 ± 6.649 (n=4; mean ± SD). 
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Figure 13. CD21
low
 CD86
pos
 B cells were larger than B cells from the other three cell 
subsets 
CD19
+
 CD20
+
 B cells were divided into four B-cell subsets according to the expression 
of CD21 and CD86 and analyzed by flow cytometry to determine cell size. (A) 
Representative donor histograms of cell size of the four B-cell subpopulations. Lines 
are color-coded for each subset corresponding to the colors in (B). (B) Box plot of the 
cell size (n=4) calculated with the MFI of the forward scatter signal (FSS). Band inside 
the box represents the median and whiskers are minimum and maximum value. 
Significant differences were calculated by one-way ANOVA with Tukey´s multiple 
comparisons test. Asterisks represent: ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. 
 
3.3.2 CD21pos CD86pos and CD21low CD86pos B-cell subsets 
were actively proliferating 
 Generally, cells have to increase their cell mass in order to progress through 
the cell cycle (Polymenis and Schmidt 1999). The Ki-67 human proliferation marker 
was used in order to determine the growth fraction of each B-cell subset. Ki-67 is a 
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protein strictly associated with cell proliferation. Hence, during interphase (G1, S, G2) 
the antigen is exclusively detected within the nucleus, whereas in mitosis most of the 
protein is relocated to the surface of the chromosomes. More importantly, the 
protein is absent from resting cells (G(0)) (Scholzen and Gerdes 2000). This makes it 
an excellent marker for determining the proportion of proliferating cells within each 
B-cell subset. Consistent with the cell size analysis, Ki-67 staining revealed that both 
CD21
pos
 CD86
pos
 and CD21
low
 CD86
pos
 B-cell subsets contained a significant larger 
fraction of proliferating cells compared to CD21
pos
 CD86
neg 
(p ≤ 0.05) (Figure 14). In 
the CD21
low
 CD86
pos 
subset, 17.42 % ± 6.168 of the cells showed higher rates of 
proliferation as measured by Ki-67 expression while 9.478 % ± 2.827 of the cells were 
proliferating in the CD21
pos
 CD86
pos
 subset. On the other hand, in the CD86
low 
subset very few cells were positive for Ki-67 with 0.1175 % ± 0.026 of CD21
pos 
cells 
and 2.120 % ± 1.195 of CD21
low 
cells (n=4; mean ± SD).  
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Figure 14. CD21
low
 CD86
pos
 B-cell subset had a higher proportion of proliferating 
cells 
CD19
+
 CD20
+
 B cells were divided into four B-cell subsets according to the expression 
of CD21 and CD86 and analyzed by flow cytometry to determine proliferation status 
by Ki-67. (A) Representative donor histograms of Ki-67 expression of the four B-cell 
subpopulations and isotype control (dotted grey line). Lines are color-coded for each 
subset corresponding to the colors in (B). (B) Box plot of the amount of cells 
expressing Ki-67 in each subset (n=4, band inside the box represents the median and 
whiskers are minimum and maximum value). Significant differences were calculated 
by one-way ANOVA with Tukey´s multiple comparisons test. Asterisks represent: * p 
≤ 0.05. 
  
3.3.3 CD21low CD86pos B-cell subset contained mostly 
antigen experienced IgMneg IgDneg class-switched B 
cells 
 B-cell subsets also differed with regard to their stage of maturation. CD21
pos
 
B-cell subsets consisted primarily of IgM
pos 
IgD
pos
 naïve B cells (68.367 % ± 9.642 of 
CD86
neg
 and 70.797 % ± 19.806 of CD86
pos 
subset), whereas CD21
low
 CD86
pos
 B-cell 
subset contained significantly more antigen experienced IgM
neg 
IgD
neg
 class-switched 
B cells (53.440 % ± 21.874; p ≤ 0.0001) (Figure 15). The CD21
low
 CD86
neg
 B-cell 
subpopulation, on the other hand, consisted of a mixture of naïve and class-switched 
B cells (42.109 % ±13.605 IgM
pos 
IgD
pos
 and 34.337 % ± 18.099 were IgM
neg 
IgD
neg
) 
(n=4; mean ± SD). 
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Figure 15. CD21
low
 CD86
pos
 subset consisted primarily of IgM
neg
 IgD
neg
 class-switched 
B cells 
CD19+ CD20+ B cells were divided into four B-cell subsets according to the 
expression of CD21 and CD86 and analyzed by flow cytometry to determine 
maturation status according to the expression of IgM and IgD. Bar charts represented 
the percentage of each subset expression of both IgM and IgD (n=7). Significant 
differences were calculated by two-way ANOVA with Tukey´s multiple comparisons 
test. Asterisks represent: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. 
3.3.4 Expression of cell surface molecules among B-cell 
subsets 
 In analogy to in vitro generated CD40B cells (section 3.1), CD21
low
 CD86
pos
 B 
cells expressed high levels of activation markers such as the costimulatory molecules 
CD80 and CD86 and had high expression of MHC class II (HLA-DR) (Figure 16A) (n=16) 
(Schultze et al. 1997). Interestingly, CD62L, which is expressed primarily by naïve B 
cells (Morrison et al. 2010) was differentially expressed on CD21
pos
 and CD21
low
 
subsets. CD62L, which is a molecule involved in early phases of migration through 
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high endothelial venules allowing transmigration into tissues, was down-regulated in 
both CD21
low
 subsets (n=13) (Figure 17A, lower right panel). Additionally and 
consistent with the hypothesis that CD21
low
 CD86
pos
 and CD21
pos
 CD86
pos 
B-cell 
subsets are antigen experienced, a significantly higher proportion of CD27
+
 B cells 
was found in CD86
pos
 subsets compared to CD86
low
 subsets (n=16, p ≤ 0.001) (Figure 
16B, upper panel). Moreover, the cell-surface glycoprotein CD43, described to be 
expressed only on a subpopulation of naïve B cells, was expressed on 84.77 % ± 13.48 
of CD21
low
 CD86
pos
 and 72.03 % ± 16.43 of CD21
pos
 CD86
pos
 B cell (n=3). In contrast, 
only 7.967 % ± 2.918 and 15.34 % ± 9.455 of CD21
pos
 CD86
neg 
and CD21
low
 CD86
neg
 
expressed CD43, respectively (Figure 16B, lower panel). The role of CD43 is not fully 
established, but it is believed to have a major function during later stages of B cell 
differentiation (Bjorck et al. 1991). Moreover, in human systems, CD43 has been 
described to be up-regulated upon activation stimuli, therefore should be considered 
as an “activation antigen” (Griffin et al. 2011). 
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Figure 16. B-cell subsets differed in terms of expression of several cell surface 
molecules 
PBMCs from healthy donors were analyzed by flow cytometry. CD19
+
 CD20
+
 B cells 
were divided into four B-cell subsets according to the expression of CD21 and CD86. 
Expression of each marker (MFI) was determined. (A) MFI of molecules associated 
with antigen presentation such as CD80 (n=16), CD86 (n=16), HLA-DR (n=15) and the 
adhesion molecule CD62L (n=13).  Data is represented as the MFI ± SD. (B) Bar chart 
showing the amount of cells (expressed as percentage -%- of B cells) that express 
CD27 (n=16) or CD43 (n=3). Significant differences were calculated by one-way 
ANOVA with Tukey´s multiple comparisons test. Asterisks represent: * p ≤ 0.05, ** p 
≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. 
 
 As shown in figure 17, phenotyping of B cells with LEGENDScreen Human 
Cell Screening (PE) Kit further confirmed these results. Additionally, relative to the 
other B-cell subsets, CD21
low
 CD86
pos B cells expressed lower levels of inhibitory 
receptors CD22 and CD32 (FcγRIIb) (n=2). CD21
low
 CD86
neg
 B cells on the other hand 
were characterized by a high expression of CD32 and a low expression of CD80, 
CD86, HLA-DR, and CD22.  
 CD32 binds IgG-immune complexes and exerts its inhibitory function by 
suppressing or blocking BCR signaling via its immunoreceptor tyrosine-based 
inhibitory motif (ITIM) upon simultaneous binding to the BCR (Nimmerjahn and 
Ravetch 2008). Besides, CD22 binds to CD45R isoforms on T cells and down-
modulates B cell activation threshold through its association with PTP-1C (SHP-1) 
(Toba et al. 2002). 
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Figure 17. CD21
low
 CD86
pos 
B cells expressed lower levels of the inhibitory receptors 
CD22, and CD32  
Purified CD19
+
 B cells from healthy donors were stained according to manufactures' 
instructions with the LEGENDScreen Human Cell Screening (PE) Kit and analyzed by 
flow cytometry to determine the expression of several markers. The size of the dots 
indicates the percentage of B cells positive for the respective cell marker. Color of the 
dots represents the z-score normalized average expression level of the indicated 
markers. Blue color denotes low expression, red color denotes high expression. The 
z-score is a statistical measurement of a score's relationship to the mean in a group 
of scores. A z-score of 0, means that the score has the same value than the mean. 
The positive and negative numbers, indicate whether the value is above or below the 
mean and by how many standard deviations. The numbers represent the z-score. 
One donor out of 2 independent experiments is shown. 
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3.3.5 Expression of molecules involved in cell trafficking 
among B-cell subsets 
 During the course of a normal immune response, lymphocytes continuously 
circulate between blood and tissues and rapidly accumulate at sites of inflammation 
(von Andrian and Mempel 2003). Molecules involved in this process of cell trafficking 
include cell adhesion molecules (such as selectines and integrins), chemokines and 
ectoenzymes (enzymes with catalytic domains outside the plasma membrane) (Salmi 
and Jalkanen 2005). Since CD40B cells were proven to induce chemotaxis of both 
CD4
+
 and CD8
+
 T cells by expression of a pattern of chemokines (see section 1.4.6) 
and to home to secondary lymphoid organs (Klein-González et al. 2010), the 
expression of relevant markers was evaluated in peripheral blood B-cell subsets. 
 CD21
low
 CD86
pos 
B cells displayed a chemokine receptor profile that appears 
to favor migration to sites of inflammation in peripheral tissues. They expressed high 
levels of CXCR3 and adhesion molecules CD18, CD11a and CD11b while expressing 
low levels of lymph node homing receptors CCR7, CXCR4 and CD62L (Figure 18 and 
Figure 16). On the other hand, CD21
pos
 CD86
pos 
B cells expressed predominantly 
lymph node homing receptors CCR7, CXCR4, and CD62L (Figure 18 and Figure 16). In 
contrast, CD21
pos
 CD86
neg and CD21low CD86neg B cells were characterized by down-
regulation of these trafficking molecules. 
 CD39, described first as an activation marker (Maliszewski et al. 1994) and 
then as an ectoenzyme (Kaczmarek et al. 1996), is a nucleoside triphosphate 
diphosphohydrolase that regulates cell trafficking by modulating adenosine levels in 
the body due to their involvement in adenosine triphosphate (ATP) metabolism 
(Salmi and Jalkanen 2005).  Therefore, CD39 expressing cells migrate towards 
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gradients at inflammation sites where ATP has been released (Antonioli et al. 2013). 
Interestingly, CD21
low
 CD86
pos 
B cells also expressed high levels of CD39 on their 
surface (Figure 18). 
  
 
Figure 18. Expression of molecules involved in cell trafficking 
Purified CD19
+
 B cells from healthy donors were stained according to manufactures' 
instructions with the LEGENDScreen Human Cell Screening (PE) Kit and analyzed by 
flow cytometry to determine the expression of several migration markers. The size of 
the dots indicates the percentage of B cells positive for the respective cell marker. 
CD19
+
 CD20
+
 B cells were divided into four B-cell subsets according to the expression 
of CD21 and CD86. The size of the dots indicates the percentage of B cells positive for 
the respective cell marker. Color of the dots represents the z-score normalized 
average expression level of the indicated markers. Black color denotes low 
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expression, red color denotes high expression. The z-Score was calculated as 
described above. One donor out of 2 independent experiments is shown. 
 
3.4 Isolation of B-cell subsets via fluorescence activated cell 
sorting (FACS) 
 Based on their phenotypic characteristics and the in vitro results of the 
CD40L experiments (section 3.1, Figure 10), it was expected that CD21
pos 
CD86
pos
 
and CD21
low 
CD86
pos
 B cells would have a higher antigen-presenting capacity 
compared to CD21
pos
 CD86
neg
 and CD21
low 
CD86
neg
 B cells. In order to assess the 
antigen-presenting capacity, the four B-cell subsets were isolated using FACS 
according to the expression of CD21 and CD86.  
 Direct sorting of B-cell subsets from PBMCs by expression of CD21 and CD86 
was not possible. The purity after isolation was never higher than 30 % especially in 
the CD86
pos 
B-cell subsets (data not shown). Therefore, a pre-separation step for B-
cell enrichment was included. In order to disturb the B cells as less as possible the 
pre-separation was done with a negative selection kit for B cells. Nevertheless, using 
this method most of the CD21
low 
CD86
pos
 B cells were lost in the process of 
separation. By screening the B-cell subsets for the molecules used for negative 
selection, a high expression of CD43 was found to be expressed by the majority of 
CD21
low 
CD86
pos
 B cells. CD43 is used to deplete T lymphocytes, monocytes and 
granulocytes, but has been also described to be expressed on a small fraction of B 
cells that happened to include most of the CD21
low 
CD86
pos 
and CD21
pos 
CD86
pos 
B 
cells (Figure 19).  
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Figure 19. The majority of CD21
low
 CD86
pos
 and CD21
pos
 CD86
pos
 B cells expressed 
CD43 on their surface 
CD19
+
 CD20
+
 B cells were divided into four B-cell subsets according to the expression 
of CD21 and CD86 and were analyzed by flow cytometry to determine expression of 
CD43. (A, B) Representative donor plots. (A) Positive cells for CD43 are marked in the 
square. (B) Plots with the appropriate isotype control for each subset. (C) Box plot 
showing the percentage of cells that express CD43 in each B-cell fraction. Horizontal 
middle line represents the median and whiskers are minimum and maximum value 
(n=3). Significant differences were calculated by one-way ANOVA with Tukey´s 
multiple comparisons test. Asterisks represent: ** p ≤ 0.01, *** p ≤ 0.001. 
 
 Since most of the commercial kits available for negative selection of 
untouched B cells contain CD43 in their mix, a CD19
+
 positive magnetic selection was 
performed. Purity of CD19
+ CD20+ B cells after CD19+ selection was always more than 
98% (data not shown). The combination of CD19
+
 selection with subsequent cell 
sorting resulted in sufficient numbers of the B-cell subpopulations with a good purity 
(Figure 20). For sorting, CD3 antibody was included to eliminate possible 
contaminating T cells. 
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Figure 20. Isolation on B-cell subsets via FACS 
B cells were purified from PBMCs via CD19 positive selection, incubated with CD3, 
CD20, CD21, CD86 and sorted by FACS according to the expression of CD21 and 
CD86. Purity of the cells after sorting is shown in the graph as a percentage of the 
total cell number for each fraction. 
 
3.5 CD21pos CD86pos and CD21low CD86pos B cells were potent 
antigen-presenting cells 
In order to proliferate, T cell required two main signals; first, activation via 
binding of the specific antigen to the TCR in the context of MHC and second, 
costimulatory signals through binding of CD80 and CD86 expressed on APCs to the 
receptor CD28 on the T cell surface (Chambers 2001).  
Assessment of the antigen-presenting capacity of B-cell subsets was done by 
means of an MLR. In order to reduce as much as possible cross-activation of T cells by 
allogeneic interactions, autologous T cells were used (Hausmann et al. 2000). In the 
autologous MLR system, the first signal is provided by the addition of OKT3. The 
target of OKT3 is the CD3 molecule, which is assembled together with the TCR 
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heterodimer. The TCR polypeptides themselves have very short cytoplasmic tails and 
all proximal signaling events are mediated through the CD3 molecule. Therefore, 
engagement of CD3 by OKT3 initiates a signaling cascade that mimics the antigen-
specific response causing T cell mitogenesis (Norman 1995, Lin and Weiss 2001). The 
OKT3 concentration was titrated in previous experiments and was combined with a 
sub-optimal concentration of IL-2, which did not induce T cell proliferation in the 
absence of costimulation (data not shown). Costimulation was the second signal and 
was provided by the APCs.  
FACS-purified and irradiated B-cell subsets were cultured with CFSE-labeled 
autologous CD3
+
 T cells. As shown in Figure 21A and B, among the four different 
subsets, CD21
low 
CD86
pos 
B cells showed the strongest T cell-stimulatory activity 
which was significantly higher than that induced by CD21
pos 
CD86
neg
 and CD21
low 
CD86
neg
 B cells (p ≤ 0.05, n=3). In line with the results from in vitro CD40B cells, the 
CD21
low 
CD86
pos
 B-cell subset showed the strongest immunostimulatory capacity 
and CD21
pos 
CD86
pos
 B cells showed an intermediate immunostimulatory activity, 
which was higher than that of CD21
pos 
CD86
neg
 B cells and CD21
low 
CD86
neg
 B cells. 
Figure 21C shows flow cytometric plots of T cells from one representative donor 
cultivated with the different controls used to determined baseline stimulation. 
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Figure 21. Mixed lymphocyte reaction with purified B-cell subpopulations and 
autologous T cells 
Sorted B cells were incubated with CFSE-labeled autologous CD3
+
 T cells for 7 days 
and proliferation and activation of T cells were evaluated by CFSE dilution and up-
regulation of CD25, respectively. (A) Dot plot showing T cell proliferation (CD25
+ 
CFSE
low
 T cells) in response to each B-cell subset of one representative donor. (B) Box 
plot with the percentage of T cell proliferation in response to each B-cell subset of 3 
donors from independent experiments. Horizontal middle line represents the median 
and whiskers are minimum and maximum value. (C) Representative FACS plots of T 
cells cultivated with the different controls (same donor from (A)). Significant 
differences were calculated by one-way ANOVA with Tukey´s multiple comparisons 
test. Asterisks represent: *p ≤ 0.05. 
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3.6 Triggering of BCR poorly induced calcium flux in CD21low B-cell 
subsets 
 Calcium signaling is important for B cell activation, proliferation, 
differentiation and function (Dolmetsch et al. 1997). After BCR crosslinking by 
antigen, downstream molecules such as SYK and BTK are phosphorylated, which in 
turn leads to activation of PLCγ2 (Kurosaki and Hikida 2009). Activated PLCγ2 
hydrolyses phosphatidylinositol 4,5-bisphosphate (PIP2) to diacylglycerol and inositol-
1,4,5-trisphosphate (IP3). The resulting IP3 binds to its receptor, which is itself a 
Ca
2+
-permeable ion channel mediating a transient calcium release from intracellular 
stores in the endoplasmic reticulum (ER) (Foerster et al. 2010). Due to the small size 
of the ER, increase in intracellular Ca
2+
 concentration is only moderated and 
transient. 
 Since the amplitude of the calcium response after BCR stimulation is 
dependent on the stage of B cell differentiation (Antony et al. 2007, Engelke et al. 
2007) and varies among B-cell subpopulations (Foerster et al. 2010), a calcium flux 
assessment was performed in the four subpopulations separately, with regards to B-
cell subset-specific differences in the initiation of cellular signaling cascade. Due to 
the low frequency of cells in each B-cell subset, a flow cytometric method was 
established to identify changes in free intracellular Ca
2+
 and to assess both basal 
status and the response to several stimuli. To do so, Fluo-3 AM and Fura Red AM 
fluorescent dyes were used. Fluo-3 is a dye which emission is 100-200 times brighter 
in the presence of Ca
2+
 than its Ca
2+
 -free form (Burchiel et al. 2000). In contrast, 
Fura Red AM experiences fluorescence quenching when Ca
2+
 is bound. Therefore, by 
analyzing the ratio of the two fluorescence emissions (Fluo-3 green to Fura Red 
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emission ratio) the sensitivity is increased (Novak and Rabinovitch 1994, Mounho and 
Burchiel 1998). These AM dyes are permeable to the cell membrane; however 
Pluronic F-127 was used to increase the penetration of dyes into the cell. Once in the 
cytoplasm, the AM esters are cleaved by esterases and dyes become sensitive to 
calcium (Burchiel et al. 2000). 
 Monitoring of both the calcium basal level and the flux of intracellular 
calcium after BCR triggering was done. CD21
low
 CD86
pos
 B cells had significantly 
higher basal intracellular calcium levels (0.320 ± 0.1522) than the other B-cell subsets 
(Figure 22A and B -red line-) (p ≤ 0.05). CD21
low
 CD86
neg 
B cells also had higher basal 
calcium levels (0.2240 ± 0.03912) than CD21
pos 
CD86
neg 
(0.1260 ± 0.06427) and 
CD21
pos
 CD86
pos 
(0.1420 ± 0.08672) B lymphocytes (Figure 22).   
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Figure 22. Baseline cytosolic calcium levels and response to BCR stimulation in the 
four B-cell subsets 
Purified B cells were incubated with the fluorescent calcium indicators Fura-Red AM 
and Fluo-3 AM for 60 min and analyzed by flow cytometry. CD19
+
 CD20
+
 B cells were 
divided into four B-cell subsets according to the expression of CD21 and CD86 (A) 
FACS plot of one representative donor calcium release in response to BCR signaling. 
Basal levels of calcium were recorded for 60 sec and then cells were stimulated with 
anti-IgM antibody. Shown is one representative donor with color-coded lines for 
each B-cell subset. Black arrow indicates the moment when stimulation with anti-IgM 
antibody was added to the sample (B) Baseline level of intracellular calcium before 
stimulation (MFI of Fluo3/FuraRed ratio) (n=5). (C) The scatter plot shows the BCR-
mediated calcium flux expressed as the ratio of the peak and baseline fluorescence 
(MFI of Fluo3/FuraRed ratio) in the four different B-cell subsets (n=6, mean ± SD). 
Significant differences were calculated by one-way ANOVA with Tukey´s multiple 
comparisons test. Asterisks represent: *p ≤ 0.05, ** p ≤ 0.01. 
 
Analysis of the response to BCR stimulation also showed a differential 
response among the subsets (Figure 22A and C). The amplitude of the response was 
calculated normalizing the peak value after stimulation to the baseline. Therefore, 
the minor the difference between baseline and peak stimulation, the closest was the 
value to 1. In CD21
pos
 CD86
neg
 and CD21
pos
 CD86
pos
 BCR engagement was followed 
by a rapid increase in intracellular calcium (3.190 ± 1.587 and 2.439 ± 0.7653, 
respectively) (Figure 22A and C). In contrast, in CD21
low
 CD86
pos
 and CD21
low
 
CD86
neg 
BCR cross-linking failed to trigger a calcium release (1.270 ± 0.1963 and 
1.585 ± 0.3263, respectively). Collectively, these results showed that CD21
low
 
CD86
pos 
and CD21
low
 CD86
neg 
B cells have an impaired calcium signaling. The higher 
intracellular calcium level before stimulation of CD21
low
 CD86
pos 
B cells and their 
decreased incremental response to BCR engagement might be related to their 
activated state. 
                                                                                                                 Results 
87 
 
To determine whether the impaired calcium signal release found on CD21
low 
CD86
pos cells was also observed in in vitro generated long term activated CD40B 
cells, the calcium response of CD40B cells against non-activated B cells (resting B 
cells) was examined. Although baseline levels of intracellular calcium were higher in 
CD40B cells, BCR cross-linking elicited intracellular calcium signals of comparable 
duration to resting B cells (Figure 23A). Unlike expected, no differences in amplitude 
of the calcium response to anti-IgM were seen compared to resting B cells (n=3, 
normalized to baseline) (Figure 23B). Thus, BCR stimulation elicited a rise in 
intracellular Ca
2+
 in both CD40B cells and non-activated B cells. 
 
Figure 23. BCR-triggering induced calcium flux on CD40B cells 
CD40 activated B cells after 21 days of culture and non-activated B cells from the 
same donors were incubated with the fluorescent calcium indicators Fura-Red AM 
and Fluo-3 AM for 60 min. Basal levels of calcium were recorded for 30 sec, cells 
were stimulated with anti-IgM and analyzed by flow cytometry. (A) Calcium release 
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of pre-treated CD40B cells (black line) or non-activated B cells (grey line) of one 
representative donor stimulated with anti-IgM (black arrow). (B) The scatter plot 
shows the calcium flux response to stimulation expressed as the ratio of the peak 
and baseline fluorescence (MFI of Fluo3/FuraRed ratio) in CD40B cells or non-
activated B cells (n=3, mean ± SD). 
 
CD40 ligation on B cells regulates several important functions such as 
induction of proliferation, immunoglobulin class switch, antibody secretion, rescue 
from apoptosis and also has a role in the development of GCs and the survival of 
memory B cells (Wykes 2003). However, the focus of the investigation of CD40 and 
CD40L interactions in most of the studies are mainly related to the NF-κB and c-jun 
N-terminal kinase signaling pathways while there is little information concerning the 
early events of signaling such as calcium flux (Schwabe et al. 2001, Zarnegar et al. 
2004). Therefore and due to the importance of calcium signaling in nearly every 
aspect of cellular life, intracellular calcium levels after CD40 ligation were 
investigated to analyze B-cell subset-specific differences. Recording of baseline 
calcium levels confirmed the results described previously in figure 22 that B-cell 
subsets differ in terms of intracellular calcium levels. However, unlike the response 
obtained after BCR engagement, CD40 ligation did not induced the release of 
intracellular calcium stores (Figure 24 A and B).   
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Figure 24. CD40L stimulation induced no calcium flux in B-cell subsets 
Purified B cells were incubated with the fluorescent calcium indicators Fura-Red AM 
and Fluo-3 AM for 60 min. Basal levels of calcium were recorded for 60 sec, cells 
were stimulated with cross-linked rCD40L and analyzed by flow cytometry. CD19
+
 
CD20
+
 B cells were divided into four B-cell subsets according to the expression of 
CD21 and CD86. (A) Calcium release in response to cross-linked rCD40L binding of 
one representative donor with color-coded lines for each B-cell subset. The black 
arrow indicates the moment when stimulation with rCD40L was added to the sample 
(B) The scatter plot shows the calcium flux response to rCD40L expressed as the ratio 
of the peak and baseline fluorescence (MFI of Fluo3/FuraRed ratio) in four different 
B-cell subsets (n=3, mean ± SD). 
 
 Since no release of calcium from intracellular stores was detected after 
CD40L stimulation, the question arose if CD40 signaling acts through opening of 
plasma membrane calcium channels. Therefore, B cells were stimulated again with 
CD40L, but this time CaCl2 was added as a source of extracellular calcium to a final 
concentration of 5 mM. Changes in intracellular calcium were only detectable when 
CaCl2 was added to the medium (Figure 25), suggesting that CD40 ligation acts 
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through regulation of calcium influx from extracellular space rather than through 
release from endoplasmic stores.   
 
Figure 25. Addition of extracellular calcium induced signaling after CD40 ligation on 
B cells 
Purified B cells were incubated with the fluorescent calcium indicators Fura-Red AM 
and Fluo-3 AM for 60 min. Basal levels of calcium were recorded for 30 sec, cells 
were stimulated with cross-linked rCD40L followed by CaCl2 as a source of 
extracellular calcium and analyzed by flow cytometry. (A) Calcium release of B cells of 
one representative donor stimulated first with rCD40L and then CaCl2. The black 
arrow indicates the moment when cross-linked rCD40L and CaCl2 were added to the 
sample (B) The scatter plot shows the calcium flux response to CD40L or CaCl2 
compare to the baseline expressed as the ratio of the peak and baseline fluorescence 
(MFI of Fluo3/FuraRed ratio) in B cells (n=3, mean ± SD). Significant differences were 
calculated by one-way ANOVA with Tukey´s multiple comparisons test. Asterisks 
represent: *p ≤ 0.05. 
 
 Similarly, when B cells were splitted into B-cell subsets according to 
expression of CD21 and CD86 no differences in terms of CD40L response after CaCl2 
were detected among the subsets (Figure 26). All B-cell subsets increased the 
                                                                                                                 Results 
91 
 
concentration of intracellular calcium once the extracellular source was added to the 
sample. 
 
Figure 26. Addition of extracellular calcium induced signaling after CD40 ligation on 
B-cell subsets 
B cells from above experiment were divided into 4 B-cell subsets according to the 
expression of CD21 and CD86 and calcium flux was analyzed individually in each 
population after CD40L and CaCL2 stimulation. (A) Calcium release of B-cell subsets of 
one representative donor stimulated first with rCD40L and then CaCl2 was added. 
Subpopulations are color-coded as described before. Black arrows indicate the 
moment when rCD40L and CaCl2 were added to the sample (B) The scatter plot 
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shows the calcium flux response to CD40L or CaCl2 compare to the baseline 
expressed as the ratio of the peak and baseline fluorescence (MFI of Fluo3/FuraRed 
ratio) in each subset (n=3, mean ± SD). No significant differences were detected by 
two-way ANOVA with Tukey´s multiple comparisons test 
 
 Next, CD40-activated B cells were compared to non-activated B cells in order 
to evaluate if the pre-activation status influences the calcium response after a 
second brief CD40 ligation. As expected, in both B-cell types there was no calcium 
flux release from intracellular stores after CD40L (Figure 27). On the contrary, it 
appears that there was less intracellular free calcium after CD40 ligation. However, 
when extracellular calcium was added, intracellular calcium in both CD40B and 
resting B cells augmented. Nevertheless, amplitude of the calcium response after 
CaCl2 was significantly higher in non-activated B cells compared to CD40B cells (p ≤ 
0.05) (Figure 27B). 
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Figure 27. CD40B cells were unresponsive to brief CD40L stimulation 
CD40 activated B cells after 21 days of culture and non-activated B cells from the 
same donors were incubated with the fluorescent calcium indicators Fura-Red AM 
and Fluo-3 AM for 60 min. Basal levels of calcium were recorded for 30 sec, cells 
were stimulated with CD40L followed by CaCl2 as a source of extracellular calcium 
and analyzed by FACS. (A) Calcium release of pre-treated CD40B cells (black line) or 
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non-stimulated B cells (grey line) of one representative donor stimulated first with 
CD40L and then with CaCl2. Black arrows indicate the moment when stimulation with 
CD40L or CaCl2 was added to the sample. (B) The scatter plot shows the calcium flux 
response to CD40L or CaCl2 respectively expressed as the ratio of the peak and 
baseline fluorescence (MFI of Fluo3/FuraRed ratio) in CD40B cells or non-stimulated 
B cells (n=3, mean ± SD). Significant differences were calculated by two-way ANOVA 
with Sidak´s multiple comparisons test. Asterisks represent: *p ≤ 0.05, ** p ≤ 0.01. 
 
3.7 CD21pos CD86pos subsets exhibited increased constitutive SYK, 
BTK and ERK phosphorylation and decreased response to BCR 
mediated stimulation 
 Signals transmitted via the BCR are central events during B cell 
development, survival, immune responsiveness and differentiation of B lymphocytes 
(Benschop and Cambier 1999, King and Monroe 2000, Niiro and Clark 2002). An 
understanding of the signaling circuitry within a cell type can provide important 
insights into its function. Therefore the signaling state was assessed with regards to 
the phosphorylation status of important signaling cascades in the four B-cell 
subpopulations. To this end, a multiplexed phospho-specific flow cytometric profiling 
was performed to detect basal as well as activation-induced signaling of intracellular 
molecules involved in B cell activation such as pZAP/SYK, BTK, pERK. Phosphorylated 
ZAP/SYK and BTK represent BCR proximal signaling events, whereas phosphorylated 
ERK, is a downstream effector protein (Figure 28) (Mackay et al. 2010). The balance 
of these signals determines the fate of the cell (Niiro and Clark 2002). 
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Figure 28. BCR induced signaling 
Overview of the signaling after BCR stimulation. Investigated phospho-proteins are 
marked in red color. Adopted from (Blix et al. 2012). 
 
 These results confirmed previously observed patterns of BCR-induced 
phosphorylation and revealed novel differences within the four B-cell subsets. First, 
differences in the basal phospho-protein levels were evaluated. For this purpose, 
samples from 11 healthy donors were analyzed by flow cytometry. The fold change in 
MFI was calculated as a transformed ratio as described by Irish et at (Irish 2014). 
Phospho-proteins in unstimulated B-cell subsets were normalized to the MFI of 
phospho-protein in CD21
pos
 CD86
neg
 B cells of the corresponding sample. Analysis of 
the baseline phosphorylation of pZAP/SYK, BTK, and pERK revealed that the CD21
pos
 
CD86
pos
 B subset displayed a higher baseline phosphorylation than the other three B-
cell subsets (Figure 29A). The most pronounced differences in baseline 
phosphorylation were present between the CD21
pos
 CD86
pos
 and the CD21
low
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CD86
pos
 B cells, which differed within basal phosphorylation of all three signaling 
molecules (Figure 29A and B). It is important to stress that the basal levels of 
phospho-proteins for the CD86
pos
 subsets were more heterogeneous compared to 
CD86
neg
 subsets as some of them showed only small changes while others had either 
higher or lower basal levels (Figure 29B).  
 
Figure 29. Elevated basal levels of phospho-proteins in CD21
pos 
CD86
pos
 B-cell subset 
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Purified B cells were stained for intracellular phospho-proteins and analyzed by flow 
cytometry. (A) Heatmap shows basal level (unstimulated) of pZAP70/SYK, BTK, and 
pERK in one representative donor. Heatmap was calculated using the arcsinh ratio of 
means normalized to the CD21
pos 
CD86
neg
 population. (B) Scatter plots of the basal 
level of 3 phosphoproteins in B-cell subsets (n=11, mean ± SD). Unstimulated 
samples were used for analysis of basal level of phospho-proteins. The transformed 
ratio was calculated with log10 (X MFI / CD21
pos 
CD86
neg 
MFI) as described by Irish et al 
(Irish 2014). Significant differences were calculated by one sample t test to the 
normalized CD21
pos
 CD86
neg
 B cells and one-way ANOVA with Tukey´s multiple 
comparisons for the other 3 groups. Asterisks represent: *p ≤ 0.05, ** p ≤ 0.01, *** p 
≤ 0.001, **** p ≤ 0.0001. 
 
Next, phosphorylation of several signaling proteins downstream of BCR, 3, 
15 and 30 minutes post BCR cross-linking were assessed (n=7). The change in MFI 
was calculated as described above and each subset-time point was normalized to the 
respective baseline MFI, i.e. before stimulation baseline MFI was set to 0. With 
regards to the BCR-triggered phosphorylation of pZAP/SYK and pERK, CD21
pos
 
CD86
neg 
showed the largest increase after stimulation. On the contrary, the other 
three
 
B-cell subsets showed a decreased response (Figure 30). Particularly, CD21
pos
 
CD86
pos
 B lymphocytes failed to phosphorylate either ZAP/SYK and ERK after BCR 
cross-linking compared to the normal response of CD21
pos
 CD86
neg
. Although after 
BCR stimulation mean phosphorylation of pZAP/SYK in CD21
low
 CD86
pos 
was lower 
than that of the other three cell subsets, differences were not significant due to 
inter-donor variations (3 min p=0.2033, 15 min p= 0.0786 and 30 min p=0.0857 
respectively, compared to CD21
pos
 CD86
neg 
subset). Importantly, phosphorylation of 
ERK after 15 min was significantly impaired in both CD86
pos
 subsets. In terms of BTK 
phosphorylation only minor changes were detected among B-cell subsets (Figure 30). 
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Figure 30. BCR induced signaling was impaired in all but CD21
pos 
CD86
neg 
B-cell 
subset 
Flow cytometry analysis of phosphorylation after BCR cross-linking of key signaling 
proteins downstream BCR. Purified B cells were stimulated with BCR cross-linking 
(anti-IgM) for 3, 15 and 30 min. (A) Scatter plots showing the differences in the 
response after BCR stimulation among the four B-cell subsets defined by the 
expression of CD21 and CD86 (n=7, mean). Changes in MFI were calculated as 
described above and expressed as transformed ratio normalized to time-point 0 
(before stimulation) of the corresponding sample. Significant differences were 
calculated to CD21
pos
 CD86
neg
 B cells by one-way ANOVA with Dunnet´s multiple 
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comparisons post and adjusted p value. Asterisks represent: *p ≤ 0.05, ** p ≤ 0.01, 
*** p ≤ 0.001. 
  
 Signaling after BCR triggering is controlled by dephosphorylation of key 
molecules by PTPs that terminate the signal (Blix et al. 2012). A low dose of H2O2 can 
regulate BCR-induced PTP activity and therefore modulates the quantity and length 
of the signaling (Irish et al. 2006). Addition of 3.3 mM of H2O2 without BCR-cross 
linking led to no significant phosphorylation of B cells in the absence of BCR 
stimulation (data not shown). When H2O2 was added immediately before BCR 
crosslinking, striking differences in BCR-induced signaling of pZAP/SYK and pERK were 
observed among the subsets (Figure 31A, B). CD21
low
 CD86
pos 
B cells showed 
significantly low and transient phosphorylation of ZAP/SYK and ERK proteins over 
time compared to the other subsets (Figure 31A and C). They also showed reduced 
phosphorylation of BTK phosphorylation that did not reach significant levels (Figure 
31C). The pattern of phosphorylation observed in CD21
pos
 CD86
pos
 was similar to 
that of CD21
low
 CD86
pos
 B cells. Thus, these results suggest that CD86
pos
 subsets 
have impaired BCR-induced signaling and that inhibition of H2O2-sensitive 
phosphatase activity cannot restore signaling in these cells. In contrast, signaling in 
CD21
low
 CD86
neg
 B cells was restored after treatment and was no longer different to 
that of CD21
pos
 CD86
neg
 B cells. Furthermore, the amplitude of the change in MFI of 
all investigated phospho-proteins was higher for all subsets compared with the BCR 
stimulation without H2O2 suggesting that H2O2-sensitive phosphatases are required 
to control the magnitude of the response (see also Figure 30).  
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Figure 31. Impaired BCR-induced 
signaling in CD86
pos
 subsets was 
not restored by inhibition of H2O2 
- sensitive phosphatases 
Purified B cells were stimulated 
with a combination of BCR cross-
linking (anti-IgM) and H2O2 for 3, 
15 and 30 min. Cells were stained 
for intracellular phospho-proteins 
and analyzed by flow cytometry. 
Bar chart showing the differences 
in the response after BCR + H2O2 
stimulation among the four B-cell 
subsets of (A) pZAP/SYK, (B) pERK 
and (C) BTK (n=2, mean ± SD). 
Changes in MFI were calculated as 
described above and expressed as 
transformed ratio normalized to 
time-point 0 (before stimulation) 
of the corresponding sample. 
Significant differences were 
calculated by one-way ANOVA 
with Tukey´s multiple 
comparisons test and adjusted p 
value. Asterisks represent: *p ≤ 
0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. 
 
 Next, phosphatase activity was completely blocked with pervanadate, a 
rapidly acting inhibitor (Wienands et al. 1996). As previously showed in figure 29, 
only CD21
pos
 CD86
pos
 B cells had elevated basal levels of pZAP70/SYK, BTK, and pERK 
while CD21
low
 CD86
neg B cells had elevated baseline of pZAP70/SYK. 
Surprisingly, upon addition of pervanadate there was a marked increase in the level 
of pZAP70/SYK only in CD21
low
 CD86
pos 
B cells. As shown in Figure 32, 5 minutes 
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after pervanadate treatment, CD21
low
 CD86
pos 
B cells contained 2.3-fold more 
pZAP70/SYK than CD21
pos
 CD86
neg
 (p ≤ 0.05) and 2.6-fold more than CD21
low
 
CD86
neg
 B cells (p ≤ 0.05) (Figure 32). The mild increase in phosphorylation of 
pZAP70/SYK in CD21
pos
 CD86
pos 
B cells was not significantly different to any other 
subset (1.3-fold to CD21
pos
 CD86
neg
 and 1.5-fold to than CD21
low
 CD86
neg
 B cells). 
The other two phospho-proteins were assessed and no differences among the 
subsets were detected (data not shown). 
 
Figure 32. Pervanadate was required for pZAP/SYK phosphorylation in CD21
low 
CD86
pos
 subset 
Purified B cells were stimulated with pervanadate for 5 min. Cells were stained for 
intracellular pZAP/SYK and analyzed by flow cytometry. Scatter plots showing the 
fold increase phosphorylation of pZAP/SYK after pervanadate treatment compared to 
unstimulated B-cell subsets (n=5, mean ± SD). Significant differences were calculated 
by one-way ANOVA with Tukey´s multiple comparisons. Asterisks represent: *p ≤ 
0.05. 
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3.8 Impaired CD40 signaling in CD21low B-cell subsets 
CD40 ligation in B cells activates both arms of the NF-ƙB pathways. Therefore 
baseline phosphorylation of NF-ƙB-p65 (n=11) and CD40L-induced phosphorylation 
of ERK and NF-ƙB-p65 were analyzed (n=7). Expression of NF-ƙB-p65 (pS529) in 
unstimulated B-cell subsets was normalized to the MFI of phospho-protein in 
CD21
pos
 CD86
neg
 B cells of the corresponding sample. Analysis of the baseline 
phosphorylation of NF-ƙB-p65 revealed that the CD21
pos
 CD86
pos
 B subset displayed 
a higher baseline phosphorylation than CD21
low
 CD86
pos 
B cells, however not 
different to that of CD21
pos
 CD86
low 
B cells (Figure 33). 
 
Figure 33. Baseline phosphorylation of NF-ƙB-p65 
Purified B cells were stained for intracellular NF-ƙB-p65 and analyzed by flow 
cytometry. (A) Heatmap show basal level (unstimulated) of NF-ƙB-p65 in one 
representative donor. Heatmap was calculated using the arcsinh ratio of means 
normalized to the CD21
pos 
CD86
neg
 population. (B) Scatter plots of the basal level of 
NF-ƙB-p65 in B-cell subsets (n=11, mean ± SD). Unstimulated samples were used for 
analysis of basal level. The transformed ratio was calculated as described before.  
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Significant differences were calculated by one sample t test to the normalized 
CD21
pos
 CD86
neg
 B cells and one-way ANOVA with Tukey´s multiple comparisons for 
the other 3 groups. Asterisks represent: *p ≤ 0.05. 
 
Phosphorylation of ERK and NF-ƙB-p65 was analyzed after 3, 15 and 30 min of 
CD40L stimulation. After 15 min, CD21
pos 
CD86
neg
 B cells have the strongest increase 
in both molecules (Figure 34, upper and lower middle panels). Nevertheless, the 
phosphorylation of ERK reached a maximum after 15 min of CD40L stimulation, 
which occurred later than that observed by cross-linking of BCR (Figure 30, pERK, left 
panel -3min-). At this time (15 min) CD21
low 
CD86
pos
 B cells had significantly less 
CD40L-induced pERK (p=0.0148) and decreased NF-ƙB-p65 (p=0.3721) compared to 
CD21
pos 
CD86
neg
 B cells (Figure 34 middle panels). Mean relative MFI levels of pERK 
and NF-ƙB-p65 in CD21
low 
CD86
pos
 B cells were 94% and 63.1% lower than in CD21
pos 
CD86
neg
 B cells, respectively. At this time-point CD21
low 
CD86
neg
 B cells had also 
significantly less CD40L-induced NF-ƙB-p65 (p=0.0421) and less pERK (p=0.2177) 
compared to CD21
pos 
CD86
neg
 B cells (Figure 34, middle panels). A similar pattern 
was seen after 30 min stimulation. Interestingly, in CD21
low
 CD86
pos 
cells 
phosphorylation pattern of NF-ƙB-p65 over the time of stimulation was highly 
heterogeneous among donors. The phosphorylation of NF-ƙB-p65 was bimodal, with 
some responding very quickly and others not responding at all. This could suggest 
that CD40L-induced phosphorylation of NF-ƙB-p65 might be differentially regulated 
in different subsets of CD21
low
 CD86
pos 
cells e.g. IgD
pos
 vs. IgD
neg
 subsets. Therefore, 
no significant differences were observed when compared to CD21
pos 
CD86
neg
 B cells 
(Figure 34, lower panels). Altogether, CD40L signaling was impaired in CD21
low
 B-cell 
subsets compared to CD21
pos 
CD86
neg
 B cells.  
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Figure 34. Impaired phosphorylation of pERK and NF-ƙB-p65 after CD40L 
stimulation in CD21
low
 B-cell subsets 
Purified B cells from healthy donors were stimulated with CD40L for 3, 15 and 30 
minutes and the expression of pERK and NF-ƙB-p65 was measured by flow 
cytometry. Shown are scatter plots of the differences in the response after CD40L 
stimulation among the four B-cell subsets defined by the expression of CD21 and 
CD86 (n=7, mean). Changes in MFI were calculated as described above and expressed 
as transformed ratio normalized to time-point 0 (before stimulation) of the 
corresponding sample. Significant differences were calculated by one-way ANOVA 
with Dunnet´s multiple comparisons test to CD21
pos
 CD86
low
 and adjusted p value. 
Asterisks represent: *p ≤ 0.05. 
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3.9 Combined CD40 engagement and BCR stimulation restored 
signaling in CD21low CD86pos subset 
BCR signaling by presentation of antigenic peptides by T cells to mature B cells 
usually leads to engagement of CD40, which in turn promotes GC formation and 
differentiation (Calderhead et al. 2000). Therefore, an experiment to identify cross-
talk between these two pathways was performed. Purified B cells were stimulated 
with a combination of anti-IgM and cross-linked, multimerized soluble CD40L for 0, 3, 
15 and 30 min (n=6). As previously described, IgM stimulation induced considerable 
and sustained phosphorylation of ZAP70/SYK and ERK on CD21
pos
 CD86
low
 B cells but 
not on the other subsets (Figure 30, ZAP70/SYK and ERK panels). In contrast, 
combination of BCR + CD40 signaling restored pZAP70/SYK in CD21
pos
 CD86
pos
 B cells 
after 3 min stimulation (Figure 35, upper left panel). Signaling was sustained until 15 
min and lost after 30 min stimulation (Figure 35, upper middle and right panels 
respectively). In CD21
low
 CD86
pos
 B-cell subset, combined stimulation induced low 
phosphorylation of ZAP70/SYK (Figure 35, upper left panel -3 min-) that was not 
different to that observed by BCR cross-linking alone (Figure 30, upper left panel). 
Interestingly, phosphorylation was sustained and increased with time, after 30 min 
reaching 3.8 times higher levels than that observed by anti-IgM stimulation alone 
(Figure 35 and Figure 30 respectively, upper right panels). In this subset, combination 
of both stimuli induced a delayed but great phosphorylation of BTK (Figure 35, BTK 
panels) that was not observed by BCR cross-linking alone (Figure 30, BTK panels). In a 
similar way, after 30 min, ERK was phosphorylated.  
Doble-negative CD21
low
 CD86
neg
 B cells had a delayed phosphorylation of 
ZAP70/SYK and BTK that was much more pronounced than that observed by BCR-
cross linking alone (Figure 35, ZAP70/SYK and BTK panels).  
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Finally, NF-ƙB-p65 was phosphorylated in all subsets but to a lesser extent 
on CD21
pos
 CD86
pos
 B cells (Figure 35, NF-ƙB-p65 middle and right panel; p=0.0377 
and p=0.0355 respectively). 
 
Figure 35. Combination of BCR and CD40 ligation restored signaling on CD21
low
 
CD86
pos
 B cells 
                                                                                                                 Results 
107 
 
Purified B cells from healthy donors were stimulated with a combination of CD40L 
and anti-IgM for 3, 15 and 30 minutes and the expression of phospho-proteins was 
measured by flow cytometry. Shown are scatter plots of the differences in the 
response after stimulation among the 4 B-cell subsets defined by the expression of 
CD21 and CD86 (n=6, mean). Changes in MFI were calculated as described above and 
expressed as transformed ratio normalized to time-point 0 (before stimulation) of 
the corresponding sample. Significant differences were calculated by one-way 
ANOVA with Dunnet´s multiple comparisons test to CD21
pos
 CD86
neg
 and adjusted p 
value. Asterisks represent: *p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. 
3.10  CD21 and CD86 delineated four functionally distinct 
peripheral blood B-cell subsets 
 The phenotypic and functional characteristics described so far, suggest that 
peripheral blood B-cell subsets defined by the expression of CD21 and CD86 
represent four functionally distinct B-cell subsets. Figure 36 summarizes the findings 
of the phenotypic and functional features of the four subsets. They differ in terms of 
the expression of activation and costimulatory molecules, cell size, proliferative 
status, antigen presentation capacity and responsiveness to BCR stimulation 
measured by Ca
2+
 flux and phospho-specific flow cytometric profiling. The figure 
suggests a hypothetical model for their function-based categorization. The majority 
of B cells consist of the CD21
pos
 CD86
neg
 B-cell subset, which is mostly composed of 
conventional resting B cells and is therefore subsequently abbreviated as Bconv. After 
short activation, Bconv up-regulate costimulatory molecules and become CD21
pos
 
CD86
pos
 B cells that seem to represent recently activated B cells (Breact), which - after 
prolonged activation - differentiate into highly immunostimulatory, antigen-
experienced CD21
low
 CD86
pos B cells (BAPC). On the contrary, CD21
low
 CD86
neg
 B cells 
appear to be functionally inactivated B cells (Binact). The model is consistent with the 
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in vitro results that suggest that CD21
low
 CD86
pos
 highly immunostimulatory B cells 
can arise from resting B cells driven by prolonged BCR and CD40L stimulation (Figure 
5C; section 1.5). However, in vivo the origin of CD21
low
 B-cell subsets remains 
unclear. 
 
Figure 36. Hypothetical model for the function-based categorization of B-cell 
subsets divided by the expression of CD21 and CD86 
Summary of the similarities and differences found in the four B-cell subsets in terms 
of activation (Act), cell size (size), proliferative status (Prolif), antigen presentation 
capacity (APC) and responsiveness to BCR stimulation (BCR). The model suggests that 
Bconv, which are conventional resting B cells after short-term activation become Breact, 
which in turn after prolonged stimulation downregulate CD21 and become BAPC. Binact 
have features of inactivated cells.  
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3.11 BAPC were increased following vaccination 
 In order to better understand the changes in B-cell subsets in response to an 
antigenic challenge, peripheral blood from healthy donors before and after 
vaccination with either influenza or hepatitis B vaccine was obtained (n=8). Following 
vaccination there was a significant increase in the frequency of circulating BAPC 
(p=0.0243) (Figure 37A). The increase was only transient and occurred within a short 
time window of 7 days after vaccination. All other B-cell subsets remained 
unchanged throughout the first two weeks (Figure 37A). This vaccine-induced surge 
in BAPC suggested that this B-cell subset plays a role in the initiation and regulation of 
the normal immune response to foreign antigens. In order to confirm the results, one 
year later with the seasonal influenza vaccination, a cohort with 10 healthy donors 
was evaluated before and one week after vaccination. Figure 37B shows that 
effectively, after 7 days of antigenic challenge, frequency of BAPC increased. It might 
be that the time frame for increase in the frequency of Breact was lost since this might 
happen shortly after vaccination. 
 
Figure 37. BAPC were increased following vaccination 
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Peripheral blood from healthy donors was collected before and after 3, 7, 10 and 14 
days of vaccine. (A) Scatter plots showing the dynamics in cell frequency after 
vaccination with either influenza (n=7) or hepatitis B (n=1) vaccine. Significant 
differences were calculated by one-way ANOVA with Tukey´s multiple comparisons 
test. Asterisks represent: *p ≤ 0.05. (B) Scatter plots from a validation cohort to verify 
increase of BAPC after 7 days of influenza vaccination (n=10, mean ± SD). Significant 
differences were calculated to day 0 (before vaccination) by paired t-test. Exact p 
values are given in the text.  
 
3.12 EBV-infected human B-lymphocytes gain a CD21low CD86pos 
phenotype in vivo 
 The experiments and analysis performed up to now were done in healthy 
donors. Therefore, to determine whether and how the four B-cell subsets are 
disturbed in human disease, peripheral blood from patients with clinically relevant 
immune-related conditions were analyzed.  
 As described in Figure 36,  B cell activation through CD40 ligation leads to 
changes in phenotype that first generated CD21
pos
 CD86
pos
 and after prolonged 
activation CD21
low
 CD86
pos
 B cells. The central role of CD40-mediated signaling for B 
cell activation and survival is further supported by the fact that EBV hijacks the B cell 
signaling machinery to immortalize B cells and promote its own survival and spread 
(Imadome et al. 2003). EBV is a human lymphotropic herpesvirus that is associated 
with several malignancies such as infectious mononucleosis and lymphoproliferative 
malignancies such as HIV-related lymphoma, Burkitt lymphoma, Hodgkin disease, 
and nasopharyngeal carcinoma (Adler et al. 2002). B lymphocytes are infected by EBV 
through the binding of gp350/220 to CD21, which is followed by internalization of 
the virus (Roberts et al. 1996). Transformation of B cells by EBV occurs via LMP1 
(latent membrane protein-1), which is encoded by the virus and mimics CD40-
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meadiated signals (Uchida et al. 1999, Peters et al. 2010). In addition LMP2A provides 
developmental and survival advantage through a surrogate BCR-like signal to 
infected B cells (Anderson and Longnecker 2008). 
It was thus a logical next step to investigate the B cells in the peripheral 
blood of patients with EBV reactivation. Since EBV-infected B cells become activated 
and are efficient APCs, they are quickly eliminated by host T cells. Therefore, EBV 
transformed B cells would hence only be expected to be present in 
immunocompromised individuals (Thorley-Lawson 2005). Consequently, peripheral 
blood B cells of patients, who underwent hematopoietic stem cell transplantation 
and had an elevated level of EBV copy numbers detected during routine monitoring, 
were analyzed. In some severely immune compromised patients, who developed an 
EBV-reactivation after allogeneic stem cell transplantation, expansion of a CD21
low
 
CD86
pos
 B-cell population was indeed identified (37.30 % ± 34.18) (Figure 38). This 
subpopulation showed similar phenotypic features as in vitro generated long-term 
CD40-activated B cells and the CD21
low
 CD86
pos
 B-cell population that was described 
early in this work in peripheral blood from healthy subjects. 
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Figure 38. BAPC were increased in patients with EBV reactivation following 
allogeneic stem cell transplantation 
Results of the analysis of peripheral blood from 7 patients with EBV reactivation 
following allogeneic stem cell transplantation. (A) Exemplary FACS plot of a patient 
with EBV-reactivation after allogeneic stem cell transplantation. (B) Scatter plot of 
the frequency of B-cell subsets in patients with EBV-reactivation after allogeneic 
stem cell transplantation (n=7, mean ± SD). 
 
3.13 The balance of CD21low B cells was altered in patients with 
inflammatory diseases 
 In order to continue the analysis of the B-cell subset homeostasis during 
disease, some prototypic inflammatory conditions were chosen. As a model for an 
acute inflammatory condition, patients with acute traumatic fractures were selected 
(Bastian et al. 2011, Claes et al. 2012). Compared to healthy controls peripheral 
blood of patients with acute traumatic fractures contained an increased percentage 
of the Breact B-cell subset (p= 0.0018, n=20) (Figure 39). 
 
                                                                                                                 Results 
113 
 
Figure 39. Breact were increased in patients with acute traumatic fractures 
Results of the analysis of peripheral blood of 20 patients with acute traumatic 
fractures compared with healthy donors. (A) Exemplary FACS plot of a healthy donor 
and a patient with a trauma, both donors are male. (B) Scatter plot of the frequency 
of B-cell subsets in patients compared to healthy donors (n=20, mean ± SD). 
Significant differences were calculated by unpaired t-test. Exact p values are given in 
the text.  
 
 Rheumatoid arthritis is one of the most common autoimmune diseases and 
affects approximately 1% of the world’s population (Finnegan et al. 2012). Active 
rheumatoid arthritis is associated with profound inflammation and autoimmune 
destruction of joints and other tissues. An important role that B cells plays in the 
pathogenesis of rheumatoid arthritis has beed demonstrated by the observation that 
B cell depletion with the monoclonal anti-CD20 antibody rituximab has proven to be 
an effective therapeutic approach for this autoimmune disease (Edwards et al. 2004, 
Samuels et al. 2005). Hence, frequency of the four B-cell subsets in rheumatoid 
arthritis was analyzed. Patients with rheumatoid arthritis had a higher frequency of 
CD21
pos 
CD86
pos 
Breact (3.233 % ± 3.916) compared to controls (1.552% ± 0.9637) 
(p=0.0055) (Figure 40A and B). Moreover, frequency of CD21
low 
CD86
pos 
BAPC (2.909 
% ± 3.828) was also increased in arthritis patients compared to controls (1.206 % ± 
0.988) (p=0.0044) (Figure 40A and B). Interestingly, synovial B cells in the joint fluid 
of two patients with rheumatoid arthritis consisted to a large part of BAPC (62.62 % ± 
9.914) (Figure 40C).  
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Figure 40. Breact and BAPC were increased in patients with rheumatoid arthritis 
Results of the analysis of peripheral blood of 39 patients with rheumatoid arthritis (2 
patients from whom was possible to obtain fluid from the joint) compared to healthy 
donors. (A) Exemplary FACS plot of a healthy donor, a patient with arthritis and joint 
fluid from the same patient, both donors were male and approximately of the same 
age (21 and 23 years respectively). (B) Scatter plot of the frequency of B-cell subsets 
in patients compared to healthy donors (n=39, mean ± SD). Significant differences 
were calculated by unpaired t-test. Exact p values are given in the text. (C) Scatter 
plot of the frequency of B-cell subsets in 2 healthy donors, 2 patients peripheral 
blood (PB) and joint fluid from the same patients (n=2, mean ± SD). Significant 
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differences were calculated by one-way ANOVA with Tukey´s multiple comparisons 
test. Asterisks represent: *p ≤ 0.05, ** p ≤ 0.01. 
 
 Several recent papers have highlighted an unexpected role for B cells in solid 
tumors. It has been described in colorectal cancer that B cells constitute a significant 
proportion of the infiltrate within the tumor microenvironment (Shimabukuro-
Vornhagen et al. 2014). Analysis of 22 tumor specimens from patients with colorectal 
cancers (CRC) revealed that CD21
low
 CD86
pos
, CD21
pos
 CD86
pos
 and CD21
low
 CD86
neg 
B cells were enriched within the tumor tissue compared to the peripheral blood of 
colorectal cancer patients and healthy controls (Figure 41 A and B). 
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Figure 41. Breact, BAPC and Binact were increased in tumors specimens of CRC patients 
Results of the analysis of peripheral blood and tumor samples of 22 patients with 
CRC cancer compared to healthy donors. (A) Exemplary FACS plot of the peripheral B 
cells from a healthy donor, a patient with CRC and B cells from the tumor of the same 
patient, both donors were male and approximately of the same age (57 and 70 years 
respectively). (B) Scatter plot of the frequency of B-cell subsets in patients peripheral 
blood and tumor compared to healthy donors (n=22, mean ± SD). Significant 
differences were calculated by one-way ANOVA with Tukey´s multiple comparisons 
test. Asterisks represent: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. 
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4 DISCUSSION 
 To date, most of the studies have been focused on the role of antigen 
presentation by B cells in mouse models (Lanzavecchia 1985, Janeway et al. 1987, 
Ron and Sprent 1987, Rivera et al. 2001, Crawford et al. 2006, Bouaziz et al. 2007). In 
humans, the study of the role that B lymphocytes play as antigen-presenting cells has 
been hampered by the lack of a phenotypically well defined subset. Therefore, the 
functional and phenotypic characterization of the recently discovered human B cell 
subset resembling CD40B cells and the establishment of a new soluble system to 
generate immunostimulatory B cells, helped to elucidate the role of this novel 
population in the human immune system both in health and disease. 
4.1 Soluble rCD40L system to generate antigen-presenting B cells  
During the past years, several in vitro models have been established to 
generate potent antigen-presenting B cells via activation through CD40. The most 
reliable and potent systems to generate CD40-activated B cells turned out to be 
those that express the ligand on a cell surface (Banchereau et al. 1991, Banchereau 
and Rousset 1991, Schultze et al. 1997, Liebig et al. 2009). Nevertheless, a cell-
standing CD40L system containing xenogeneic components has several 
disadvantages. It not only incorporates a source of contamination that could 
interfere with experimental observations but also represents a limitation to transfer 
the system to the clinical settings.  
In this work, the tested soluble human rCD40L proved to be as potent as the 
well-known NIH3T3/tCD40L system at inducing activation and proliferation of B cells 
with the advantage of elimination of xenogeneic contaminations. Therefore, 
development of this efficient rCD40L is an important step to facilitate the potential 
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use of CD40B cells in human clinical trials. Moreover, previously described features of 
CD40B cells were confirmed by the characterization of activated B cells generated by 
both CD40L systems. They both up-regulated the expression of HLA-DR, CD80 and 
CD86 and had high capacity to induce activation and proliferation of allogeneic T cells 
(Schultze et al. 1997).  
The importance of clustering of the CD40L was evidenced by low 
proliferation rate of B cells induced by CD40L in the absence of the cross-linking 
antibody. Although CD40L is found in vivo on the cell surface as homotrimer, it has 
been shown that  homotrimerization is necessary but not sufficient for maximal 
activity (Haswell et al. 2001). Therefore, clustering of CD40 is required for optimal 
CD40 signaling (Fanslow et al. 1994, Morris et al. 1999, Stone et al. 2006, Naito et al. 
2013). 
 Moreover, by using this in vitro model for generation of CD40B cells it was 
possible to compare and confirm similarities between BAPC and long term activated 
CD40B cells. They resemble each other in terms of high expression of costimulatory 
molecules CD80 and CD86, low expression of CD21 and CD32 and more importantly, 
both are highly efficient antigen-presenting B cells and induced activation and 
expansion of T cells. All these features are recognized to be characteristics of 
professional antigen-presenting B cells (Rodríguez-Pinto 2005). Therefore, these 
results suggest that CD40-activated human B cells represent a valuable in vitro model 
to study the properties of BAPC. 
Additionally, in the future, this in vitro model could be applied to develop 
BAPC-based targeted therapies. In diseases such as arthritis where a high frequency of 
BAPCs was observed, therapeutic agents that specifically deplete these cells might 
result in the amelioration of the symptoms. 
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4.2 The CD21low population  
 To date, populations characterized by a low expression of CD21 have been 
described in several pathological conditions such as CVID, SLE, hepatitis B, viremic 
HIV infection and rheumatoid arthritis (Warnatz et al. 2002, Wehr et al. 2004, Moir et 
al. 2008, Rakhmanov et al. 2009, Isnardi et al. 2010, Charles et al. 2011, Visentini et 
al. 2012). An increase in the frequency of CD21
low
 B cells is the reflection of the 
disturbance in the homeostasis of circulating subsets in such diseases. This 
homeostasis is maintained under physiological conditions by controlled pro- and 
anti-inflammatory forces. When the balance is disrupted, alterations in the frequency 
of subsets are evident. 
  Most of the functional assays done to characterize the CD21
low
 population 
described in such diseases revealed that they are functionally attenuated 
(Rakhmanov et al. 2009), anergic (Isnardi et al. 2010) or exhausted (Moir et al. 2008) 
B cells.  Nevertheless, none of the groups studied the function of CD21
low
 population 
in healthy individuals.  
 In this study, healthy donor-derived peripheral blood B cells classified in four 
subsets according to the expression of CD21 and CD86 were characterized 
phenotypically and functionally. Low frequencies of CD21
low
 B cells were detected in 
healthy donors, but surprisingly, these B cells were further separated into two 
functionally different subpopulations by the expression of CD86. 
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4.3 Functional and phenotypic characterization of B cells classified 
by the expression of CD21 and CD86 revealed striking 
differences among subsets 
In addition to the differential expression of CD21 and CD86 surface 
molecules, B-cell subsets differed in several other features. 
4.3.1 CD21pos CD86neg Bconv subset 
Like naive B cells,  CD21
pos
 CD86
neg
 Bconv cells were characterized by a small cell 
size, low frequency of Ki-67
+
 cycling cells, absence of expression of activation, 
costimulatory and memory markers and a non-switched IgM
pos 
IgD
pos
 phenotype 
(Duty et al. 2009). Furthermore, they were positive for the BCR-associated regulator 
CD22 that is expressed on mature B cells (Tedder et al. 1997). Moreover, since they 
expressed neither the T cell costimulatory molecule CD80 nor CD86, when cultivated 
with autologous T cells they induced very low stimulation. As expected Bconv showed 
low basal calcium and phosphorylation levels and a robust response after stimulation 
evidenced by calcium and phosphorylation signaling (Duty et al. 2009).  
These phenotypic and functional characteristics corresponded to mature 
resting B cells that were recirculating throughout the body and had not yet 
encounter their cognate antigen.  
4.3.2 CD21pos CD86pos Breact subset 
In agreement with previous data on activated B cells, double positive Breact 
subset showed a characteristic phenotype with increased expression of CD80, CD86, 
CD43 and HLA-DR (Sarkar et al. 1980, Azuma et al. 1993, Boussiotis et al. 1993, Griffin 
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et al. 2011). Up-regulation of these molecules coincided with an increased cell size 
and a higher frequency of proliferating Ki-67
+
 cells compared to other populations 
(Sarkar et al. 1980). Additionally, most of Breact cells were CD27 positive. Interestingly, 
most of the cells in the Breact subset had a “natural effector” phenotype described by 
Brekowska et al., by expression of CD27
+
 IgM
pos 
IgD
pos 
B cells (Berkowska et al. 
2011). Berkowska et al., characterized these cells by a limited proliferation, reduced 
replication history and SHM levels compared to GC B cells. They also found them in 
CD40L-deficient patients. As a result, the authors concluded that this phenotype is 
expressed by B cells that were derived (at least in part) from systemic GC-
independent responses. However, the origin of these cells is controversial, since 
another group has reported that they could be derived from T-cell-dependent GC 
reactions (Seifert and Kuppers 2009). From the in vitro results of CD40L activation 
obtained in this study, it could be hypothesized that Breact are activated B cells that 
had recently encountered their cognate antigen. They are probably trafficking 
towards the secondary lymphoid organs, where usually they encounter both antigen 
bound to follicular DCs and CD40L-mediated T-cell help. At this point, at least part of 
them will undergo further selection and class-switch recombination in the GC 
reaction.  
Consistently, Breact expressed higher levels of receptors CD62L, CCR7 and 
CXCR4 than BAPC and Binact which have been associated with migration to lymph nodes 
(Butcher and Picker 1996, Gunn et al. 1999, Hiller and Chu 2011). Additionally, Breact 
expressed CCR6 which has been shown to be transiently up-regulated after activation 
(Wiede et al. 2013). Moreover, and consistent with the hypothesis that the 
immunostimulatory activity increases with the duration of the stimulus and 
decreasing expression of CD21, the antigen-presenting capacity of Breact was 
intermediate between Bconv and BAPC.  
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Analysis of the basal phosphorylation in Breact showed active ZAP70/SYK, BTK 
and pERK, which might suggest that they are actively in cell cycle (Gururajan et al. 
2006). This is consistent with the high rate of proliferation observed by Ki-67 analysis. 
In this subset, changes in phosphorylation after stimulation were lower compared to 
Bconv in part because these cells had a higher basal level of activation. 
Moreover, since Ca
2+
 signaling was not impaired in this B-cell subset, it can be 
suggested that the constitutive phosphorylation of the analyzed elements was 
independent of PLCɣ2. However, further signaling analysis have to be performed to 
elucidate the pathway that controls such activated state. 
Taken together, these characteristics might suggest that the Breact subset 
developmentally represents a transitional stage between Bconv and BAPC. 
4.3.3 CD21low CD86pos BAPC subset 
 CD21
low
 CD86
pos
 BAPC subset shares some characteristics with Breact cells. They 
both had increased cell size and a higher proportion of proliferating cells compared 
to the Bconv and Binact subsets. They both over-express CD80, CD86, CD43 and HLA-DR 
consistent with an activated phenotype. These characteristics are in agreement with 
the in vitro results of CD40B cells (section 3.1). Therefore, CD21
low
 CD86
pos
 BAPC 
seems to represent activated B cells that have undergone continuous or repeated 
stimulation. Presumably, constant stimulation through BCR and the influence of 
other pro-inflamatory signals, such as CD40 ligation, could have lead to this activated 
phenotype.  
 It is probable that the effect of the activation stimuli was potentiated by the 
down-modulation of inhibitory receptors i.e. CD32 (FcγRIIb) and CD22, seen on this 
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subset. Thus, reduced levels of these proteins would have resulted in a lower 
threshold for B cell activation. Consistently, recent data suggests that the aberrant 
expression and function of CD32 on B cells is important in the pathogenesis of 
various autoimmune diseases (Nimmerjahn and Ravetch 2008, Smith and Clatworthy 
2010). More specifically, in a mouse model was shown that CD32 gene deficiency 
increases both the susceptibility to autoimmunity and disease severity (Bolland and 
Ravetch 2000, Nakamura et al. 2003).  
In line with the hypothesis that BAPC underwent several rounds of stimulation, 
most of the cells in this subset expressed CD27, recognized to be a marker for human 
memory B cells (Agematsu et al. 2000). Since, memory B cells are mainly generated in 
secondary lymphoid organs in GC reactions after antigen encounter, it can be 
suggested that most of the BAPC are antigen experienced. Furthermore, the analysis 
of their class-switched profile confirmed this result. Classical memory B cells are 
CD27
+
 class-switched IgM
neg 
IgD
neg that are derived from T cell-dependent 
responses, have high levels of activation and costimulatory molecules and an 
extensive replication history (Good et al. 2009, Berkowska et al. 2011). Such 
characteristics correspond to the majority of BAPC, which as proposed by van Zelm et 
al., are features of cells that already underwent additional immune responses in 
secondary and tertiary antigen encounters (van Zelm et al. 2007). Interestingly, the 
switched IgM
pos
 BAPC subset could either arise through a GC-independent route, as 
proposed by Taylor et al., or as described by Klein et al., they could be early 
emigrants from a primary GC response without participating long enough in the 
reaction for isotype switching to occur (Klein et al. 1997, Taylor et al. 2012). Either 
way, BAPC subset seems to be composed of antigen-experienced cells. 
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Excitingly, an additional feature shared by CD40B cells and BAPC was detected. 
They both displayed a higher expression of the integrins CD11a/CD18 and CD11b 
which are involved in migration from peripheral blood to sites of inflammation 
(Barrett et al. 1991, Kawai et al. 2011). These results suggest that migration capacity 
of BAPC out of peripheral blood is markedly superior compared to the other three B-
cell subsets. However, based on their chemokine receptor profile, BAPC appears to be 
poised to home to sites of inflammation in peripheral tissues, while CD40B cells have 
been described to home to secondary lymphoid organs (Klein-González et al. 2010). 
In this way, BAPC expressed high levels of CXCR3, CD39, CD18, CD11a and CD11b and 
low levels of the lymph node homing receptors CCR7, CXCR4 and CD62L. Interestingly 
and consistent with the notion that BAPC home to peripheral tissue, it was found in 
the synovial fluid from two rheumatoid arthritis patients that the majority of the B 
cell infiltration was of the phenotype CD21
low 
CD86
pos BAPC. Consistently, the 
frequency of these B cells was also increased in tumors of CRC patients.   
Therefore, BAPC possessed the phenotypic characteristics of antigen-
experienced post-germinal center B cells. They might represent a transitional stage 
between GC B cells and plasma cells. Besides, they still express CD20, which is lost 
during differentiation at the plasmablast stage (Jego, Bataille et al. 2001) and they 
did not express CD138 (data not shown), which is acquired by differentiated plasma 
cells (Klein and Dalla-Favera 2007). Antibody secretion by BAPC remains to be tested.   
In agreement with the fact that BAPC expressed more costimulatory molecules 
than other subsets, it was not surprising that they exhibited the most efficient 
antigen-presenting capacity as tested by means of an autologous MLR. This is 
consistent with the in vitro findings described here and by others that showed that 
CD40B cells possessed a potent immunostimulatory activity (Faassen et al. 1995). 
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Thus, CD21
low
 CD86
pos
 BAPC subset efficiently stimulated autologous T cells. More 
importantly, this functional characteristic was mainly restricted to the CD21
low
 
CD86
pos
 B-cell subset. 
Signaling analysis after BCR-stimulation revealed that BAPC as well as Binact not 
only had an increased basal calcium level but a poor calcium release after further 
BCR-stimulation. This is in line with one study where analysis of calcium signaling on 
CD21
low
 B cells from healthy donors revealed that this population had physiologically 
lower Ca
2+
 signaling response than the naïve IgD
pos
 B cells after BCR-crosslinking 
(Foerster et al. 2010). Since this attenuated response was not seen in the other two 
B-cell subsets (Breact and Bconv) it is thus tempting to speculate that the defect in the 
mechanism regulating Ca
2+ 
in CD21
low
 subpopulations is specific for mature, class-
switched B cells. The low calcium response seen in these subsets, cannot be 
attributed to the low expression of CD21 itself since Thiel et al. reported that a 
patient with a genetic CD21 deficiency that abolished surface expression of the 
protein had normal calcium flux (Thiel et al. 2012). They found that in CD21-deficient 
B cells, calcium flux triggered by C3d-containing immune-complex was completely 
abolished while the response triggered directly through the BCR alone was 
completely normal, indicating that CD21 is not required for generating a Ca
2+
 signal. 
Moreover, as previously described by Galibert et al., BCR stimulation of long 
term activated CD40B cells induced a substantial calcium release comparable to that 
of non-activated B cells, even though like BAPC, CD40B cells exhibited higher basal 
calcium levels (Galibert et al. 1996). These results suggest that the proximal events of 
BCR signaling transduction, e.g. activation of PLCɣ2, are operative in CD40-activated 
B cells, which might not be the case for the BAPC subset. 
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One potential mechanism that could account for reduced BCR responsiveness 
of BAPC could be a high constitutive downstream signaling. To address this issue, 
specific mediators of intracellular signaling were analyzed by multi-parameter 
phosphoflow and revealed that BAPC were less responsive to BCR stimulation 
compared to Bconv. This result coupled to the high calcium baseline and low calcium 
release suggested signs of previous activation. However, activation should be 
reflected in basal phosphorylation of intracellular mediators. Surprisingly, analysis of 
the baseline activation of intracellular signaling elements did not provide evidence of 
constitutive activation in BAPC subset, but yet downstream signaling was interrupted 
as evidenced by the poor BCR-induced phosphorylation of ERK compared to Bconv 
cells. This phenomenon was not mediated by a high phosphatase activity, since 
treatment with H2O2 was not able to restore the BCR-signaling propagation in this 
subset. An additional explanation might be that signaling elements in CD21
low
 
CD86
pos
 BAPC are being actively and continuously phosphorylated and 
dephosphorylated. To test this hypothesis, phospho-proteins were evaluated in the 
presence of pervanadate. Pervanadate is a rapidly acting phosphatase inhibitor 
(Wienands et al. 1996), which have been also shown to activate intracellular tyrosine 
kinases that are normally retained in inactivated state by dephosphorylation (Trudel 
et al. 1991, Teshima et al. 1994). Interestingly, pervanadate treatment increased the 
baseline level of pZAP70/SYK only in the BAPC subset. As proposed by Holodick et al., 
these results might suggest that ZAP70/SYK is being continually and rapidly 
phosphorylated, and just as rapidly dephosphorylated (Holodick et al. 2009). This 
suggests that in BAPC, phosphorylated ZAP70/SYK protein is persistently turning over 
and hence steadily signaling. Consistently, inhibition of ZAP70/SYK has shown 
promising results in rheumatoid arthritis patients characterized by B-cell 
hyperactivity (Ghosh and Tsokos 2010).  
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Since individual signaling pathways are not acting alone but interconnecting 
and influencing each other to lead to a biological response, cross-talk between BCR 
and CD40L stimulation was evaluated in the four B-cell subpopulations. When B cells 
were stimulated with CD40L alone, both CD21
low 
subsets showed impaired signaling 
of the canonical pathway NF-κB (p65) and ERK. However, concurrent activation with 
both stimuli was able to restore signaling in CD21
low
 subsets, which was translated in 
a delayed but greater phosphorylation of SYK, BTK, ERK and NF-κB-p65 that was 
higher on BAPC than in Binact. This result indicates that BAPC exhibited a higher 
sensitivity to CD40-mediated signaling when combined with BCR stimulation. It might 
be that simultaneous stimulation activates an alternate pathway that circumvents 
the early events (i.e. calcium flux) that were shown to be disrupted in CD21
low
 
subsets to ultimately lead to phosphorylation of ERK and NF-κB. This is in line with a 
previous report in which an alternate pathway in PLCγ2-inhibited B cells stimulated 
with CD40L was described (Mizuno and Rothstein 2005). Collectively, the signaling 
assays demonstrate that BAPC are in an activated state and that the four B-cell 
subpopulations exhibited differential downstream activation of the signaling 
pathways.  
4.3.4 CD21low CD86neg Binact subset 
CD21
low
 CD86
neg 
Binact subset represented most of the CD21
low
 B-cell 
compartment. In contrast to BAPC, they were characterized by a small cell size, low 
proliferative rate as measured by Ki-67 positivity, low expression of costimulatory 
molecules, high expression of CD32, down-regulation of trafficking molecules and a 
very low capacity to induced T cell activation.  
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The absence of chemokine and trafficking receptors was previously reported 
in CD21
low
 anergic B cells, suggesting that down-regulation of these receptors is likely 
to exclude them from follicles, to recruit them in GCs or to favor their eventual 
elimination in specific compartments (Cyster et al. 1994, Cyster and Goodnow 1995, 
Isnardi et al. 2010). Altogether, Binact subset expressed a set of molecules that might 
help to prevent their activation. 
Most of these features have been associated with mouse anergic B cells 
(Cambier et al. 2007). In fact, an anergic, autoreactive CD21
low 
population with these 
characteristics was previously described in CVID and SLE patients and in persons 
infected with HIV and HCV (Wehr et al. 2004, Moir et al. 2008, Rakhmanov et al. 
2009, Charles et al. 2011). They represented a population of autoreactive B cells that 
escaped central tolerance mechanisms and were silenced in the periphery by an 
induced state of lethargy, probably as a result of an antigenic challenge (self- or viral) 
in the absence of costimulatory signals that sustained their activation (Cambier et al. 
2007).  
In mouse anergic B cells, down-regulation of CD21 was associated with an 
increased BCR signaling threshold and an inability to be activated (Hartley et al. 1993, 
Nguyen et al. 1997). Moreover, as reported by Lyubchenko et al., cross-linking of 
CD21 and BCR was enough to overcome B cell anergy (Lyubchenko et al. 2007). By 
using an Ars/A1 murine model of B cell anergy independent of CD21 down-
regulation, they studied the effects of complement-mediated signaling in anergic B 
cells. They found that unlike BCR stimulation alone, BCR/CD21 costimulation of 
anergic Ars/A1 B cells led to calcium mobilization in vitro and the production of 
autoantibodies in vivo. These findings further suggest that CD21 down-regulation 
contributes to B cell anergy in mice and humans. In addition to the low expression of 
CD21, the up-regulation of the inhibitory cell surface receptor CD32 could as well be 
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influencing the functional consequences of the BCR signaling response (Nimmerjahn 
and Ravetch 2008). 
Furthermore, Binact cells were constitutively phosphorylated in tyrosine 
residues Y319 and Y352 on ZAP70/SYK compared to Bconv cells. This is in contrast to 
the results of Visentini et al., who described an exhausted marginal zone-like CD21
low
 
B-cell population with attenuated BCR signaling but constitutive activation of ERK in 
healthy donors as well as in hepatitis C virus (HCV)-associated mixed 
cryoglobulinemia (Visentini et al. 2012). However, their population was characterized 
by the expression of a VH1-69-encoded idiotype and although they indicated to be a 
CD21
low
 subset, it was actually a mixture of CD21
low
 and CD21
pos
 B cells. In the 
CD21
low
 CD86
neg 
Binact subset, constitutive expression of ZAP70/SYK was not 
accompanied by constitutive expression of activated forms of signaling mediators 
that would be expected if phosphorylation of ZAP70/SYK were produced by cell 
“activation”. Moreover, after BCR stimulation, downstream induced phosphorylation 
of ERK was triggered. For these reasons, the presence of pZAP70/SYK and the higher 
baseline Ca
2+ 
level in this subset might be the reflection of isolated ZAP70/SYK 
activation, possibly as a result of aberrant Src family kinase activity, or as a reflection 
of previous activation events that have long since run their course and are no longer 
present. Consistently, overexpression of phosphatases evidenced by the restored 
BCR-signaling after H2O2 treatment might be the reason why constitutive activation 
of ZAP70/SYK was not inducing accumulation of pERK in this subset. 
These results corroborate earlier findings that the CD21
low
 B-cell subset 
predominantly consists of functionally impaired B cells with features consistent with 
an anergic or exhausted state. Therefore, CD21
low
 CD86
neg 
B cells seem to represent 
the healthy counterpart to the anergic-exhausted and expanded population 
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described by others in CVID, SLE, hepatitis B, viremic HIV infection and rheumatoid 
arthritis (Warnatz et al. 2002, Wehr et al. 2004, Moir et al. 2008, Rakhmanov et al. 
2009, Isnardi et al. 2010, Charles et al. 2011, Visentini et al. 2012).  
4.4 Calcium flux signaling in B cells after CD40L stimulation 
 There is little information available concerning the early events of signaling 
after CD40 ligation. Therefore, signaling of calcium was analyzed in the four B cell-
subsets after CD40L stimulation. Interestingly, in this setting, CD40L acted 
independently of intracellular calcium release from endoplasmic stores and induced 
no calcium response in any of the studied B-cell populations. 
 These results were surprising since at least one study showed that binding of 
CD40 elicited PLCγ2 activation on B cells and increased IP3 kinase activity, which in 
turn is essential for calcium release from ER stores (Kashiwada et al. 1996). 
Nevertheless, studies done with PI3K
-/- 
mice reported normal PLCγ2 phosphorylation 
after stimulation, although Ca
2+
 mobilization was only 25 % of normal (Clayton et al. 
2002). Therefore, normal tyrosine phosphorylation of PLCγ2 does not necessarily 
imply full PLCγ2 activation. Additionally, another study showed that CD40 
engagement on pro-B-, pre-B-I, pre-B-II, or activated mature tonsillar B cells but not 
on naïve mature B cells resulted in enhanced tyrosine phosphorylation and a rapid 
increase in the production of IP3 (Uckun et al. 1991). The CD40 receptor signaling 
they detected, occurred in buoyant tonsillar B cells consisting predominantly of 
IgM
neg 
GC B cells as well as in immature IgM
neg 
B-cell precursors, but not in strongly 
IgM
pos 
dense tonsillar B cells. This is consistent with another study, which showed 
that anti-CD40 mAb did not induce an increase in tyrosine phosphorylation in dense 
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tonsillar B cells even though this population is highly responsive to IgM stimulation 
(Lane et al. 1990). 
 Therefore, general conclusions should be taken with care, because most of 
the studies were performed with different cellular models. It might be that signaling 
through CD40L on B cells is dependent on the developmental as well as activation 
stage of the B-cell subset or that peripheral blood B cells are responding to CD40L in 
an independent fashion from calcium release from intracellular stores.   
Interestingly, when a source of extracellular calcium was included, an increase 
in the Ca
2+
 response of B cells was observed in all the studied populations. This result 
suggests that the Ca
2+
 signaling after CD40L relies on mechanisms regulating Ca
2+
 
influx from the extracellular space downstream of PLCγ2 activation and IP3 receptor-
mediated release of Ca
2+
 from ER stores.  
4.5 B-cell subset homeostasis is disturbed in some diseases 
After phenotypic and functional analysis of the four B-cell subsets in healthy 
individuals, it was clear that Bconv, Breact, BAPC, and Binact populations are functionally 
different and possesses unique features. Since the current literature shows that 
many inflammatory diseases in humans are accompanied by a perturbation of the 
balance of the CD21
low
 B-cell compartment, it was not surprising to find an imbalance 
in the homeostatic state of the four B-cell subsets in the selected medical conditions. 
Therefore, acute inflammation (trauma patients) resulted in an increase in CD21
pos
 
CD86
pos
 Breact while CD21
low
 CD86
pos
 BAPCs were increased in autoimmune diseases 
(rheumatoid arthritis) as well as in cancer as a model for chronic inflammatory 
condition. These results are in line with the hypothesis that Breact are generated after 
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short stimulation and that prolonged CD40 or BCR stimulation leads to the 
accumulation of BAPCs. 
It is important to note that the classification of B cells by the expression of 
CD21 and CD86 further dissected the CD21
low
 B-cell population previously described 
to be composed of anergic, exhausted, auto-reactive B cells into two subsets with 
distinct functions. On the one hand, CD21
low
 CD86
neg
 Binact with the exhausted 
phenotype seems to represent the subset previously described in CVID patients 
(Warnatz et al. 2002) while CD21
low
 CD86
pos
 BAPC with an activated phenotype and 
potent antigen-presenting capacity were found to be increased in rheumatoid 
arthritis patients. Interestingly, it was previously described that CVID but not 
rheumatoid arthritis patients contain elevated serum levels of B cell-activating factor 
(BAFF), which has been associated with an increased survival of auto-reactive B cells 
in mice, likely contributing to the accumulation of these cells in CVID patients (Lesley 
et al. 2004). Moreover, CVID patients who display higher frequencies of CD21
low
 B 
cells are more susceptible to develop autoimmune syndromes (Isnardi et al. 2010). 
This suggests that accumulation of CD21
low
 CD86
neg
 Binact cells may contribute to the 
development of autoimmunity in humans. Immune reactions may create a favorable 
environment in which tolerance is broken and CD21
low
 CD86
neg
 Binact cells are 
eventually activated to CD21
low
 CD86
pos
 BAPC. Thus, both CD21
low
 B-cell subsets seem 
to arise from antigen-experienced B lymphocytes. In the case of BAPC, additional T cell 
help was received through CD40-mediated signals allowing them to become fully 
activated inflammatory effector B cells while Binact received no or insufficient T cell 
help.  
The expanded population of BAPC found in rheumatoid arthritis patients might 
be favoring a more productive interaction with pathogeneic T cells. In mice for 
example, it has been shown that antigen-specific B cells with high expression of MHC 
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class II, and costimulatory molecules CD80 and CD86 are required for the induction of 
arthritis (O'Neill et al. 2005). As mentioned above, presumably repeated stimulation 
of autoantigens through BCR plus the influence of other proinflammatory signals, 
such as cytokines or CD40L stimulation, gave rise to this activated phenotype, which 
has been reported in other diseases such as systemic sclerosis (Sato et al. 2004), 
asthma (Hofer et al. 1998) and irritable bowel syndrome (Ohman et al. 2009). The 
described absence of inhibitory molecules on BAPC might account for this 
phenomenon since such regulatory molecules provide a negative feedback that limits 
the ongoing self-reactive humoral responses (Catalan et al. 2010). In fact, in an SLE 
mouse model, restoration of the expression of CD32 on B cells diminished the 
symptoms and reverted the secretion of autoantibodies (McGaha et al. 2005).  
Interestingly, in healthy individuals a higher percentage of BAPC was observed 
in women compared to men of the same age, an observation which is in line with a 
previous report that women have a higher risk of developing autoimmune disease 
(Amur et al., 2012). 
In the observed conditions a shift in the balance towards the BAPC subset could 
be indicating the generation of an inflammatory B cell response. Indeed as observed 
with the influenza vaccinated cohort, the BAPC subset was increased 7 days after 
vaccination indicating the involvement of this B-cell population during the course of 
the physiologic immune response to vaccines. This is consistent with an study from 
Jahnmatz et al., in which after 7 and 14 days of intranasal vaccination with an 
attenuated Bordetella pertussis vaccine they found an increase in CD21
low
 CD27
pos
 B 
cells (Jahnmatz et al. 2014). Although the antigen-specificity of the B cells was not 
investigated, it is most likely that such increase on BAPC was induced by the vaccine, 
since the frequency of the other B-cell subsets was not altered. 
                                                                                                           Discussion 
135 
 
Each condition was associated with a characteristic imbalance of the 
homeostatic state within the B-cell compartment. Acute inflammation resulted in an 
increase in Breact while a shift towards the BAPC subset could indicate the generation of 
an inflammatory B cell response, like response to vaccination or disease activity in 
human autoimmune disease. The data demonstrated that there are important 
alterations in the homeostasis of peripheral blood B-cell subsets involving the 
expression of the costimulatory molecules CD86 and CD21 in chronic and acute 
diseases, suggesting that these cells indeed play a role during the course of an 
immune response. 
 This research project has important clinical implications. The analysis of the 
frequency of each B-cell subpopulation could serve as a promising biomarker for 
disease activity and response to treatment in many immune-mediated diseases. 
Furthermore, dysregulated subsets could be therapeutically targeted as an effective 
approach for the treatment of many B-cell mediated immune pathologies. In this 
way, depletion of B cells using monoclonal anti-CD20 antibodies has been shown to 
be an effective therapeutic strategy in several medical conditions including cancer, 
autoimmune diseases, graft-versus-host disease, and transplant rejection 
(McLaughlin et al. 1998, Shimabukuro-Vornhagen et al. 2009, Barnett et al. 2013, 
Bindea et al. 2013, Pateinakis and Pyrpasopoulou 2014). However, B cell subset-
specific therapies would be advantageous. Unfortunately, the cell surface markers 
described here to characterize the subpopulations are not suitable for targeting 
these subsets. Further research should be done in order to identify specific-cell 
surface markers that are amenable for a therapeutic depletion of these subsets with 
monoclonal antibodies. In addition, the establishment of the novel soluble model to 
generate CD40-activated B cells showed to be an effective in vitro model to produce 
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large amounts of BAPC. In the future, this model could be used for the development of 
BAPC-specific targeted therapies.  
  
4.6 Conclusion 
Taken together, the data presented in this work demonstrated that human B-
cell subsets divided by the expression of CD21 and CD86 represent phenotypic and 
functionally different B-cell populations. In vitro data sustained the hypothesis that 
CD21
pos
 CD86
pos
 subset can develop from resting naïve B cells after T cell help 
through CD40L and that prolonged stimulation results in down-regulation of CD21. 
Therefore, it is tempting to suggest that in vivo CD21
low
 CD86
pos
 BAPC likewise arise 
from CD21
pos
 CD86
pos
 Breact by sustained BCR- and CD40-driven activation. 
Collectively, the results provide a conceptual framework for the division of human B 
cells into functional subsets. 
Both CD21
low
 B-cell subsets seem to arise from antigen-experienced B 
lymphocytes. They were proven to be functionally different and to differ in the 
expression of several molecules and inhibitory receptors. CD21
low
 CD86
pos
 BAPC were 
shown to be fully activated memory B cells with a strong immunostimulatory 
capacity while CD21
low
 CD86
neg
 Binact subset contained primarily inactivated B cells, 
which displayed evidence of exhaustion or anergy. Additionally, BAPC were increased 
in patients with autoimmune diseases and cancer indicating that they might play a 
role in the induction of pathogenic responses. Hence, it could be suggested that in 
autoimmunity, breaking of tolerance mechanisms might be contributing to the 
pathogenesis of the disease by the activation of auto-reactive CD21
low
 CD86
neg
 Binact 
that eventually would become CD21
low
 CD86
pos
 BAPC.  
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 It is important to mention that in order to further dissect the molecular 
mechanisms that determine the development of CD21
low
 CD86
pos
 BAPC an analogue to 
this B-cell subset have to be identified in a mouse model. The main problem is that in 
mice and humans the expression of CD21 is regulated differently (McGaha et al. 
2005). In the human system, two separate genes which lie in close vicinity on 
chromosome 1q encode CD21 and CD35 (Fujisaku et al. 1989). However, in mice 
these two proteins are encoded within the CR2 locus and are generated from one 
gene by means of differential splicing (Erdei et al. 2009). Therefore, there are no 
available knockout mice for only one of these proteins, and thus the phenotype 
might not reflect the phenotype of human B cells lacking only CD21.   
 Furthermore, major differences between the two species have been 
identified in terms of the genetic background, tissue distribution, cytoplasmic 
sequences and their role in B cell functions (Jacobson and Weis 2008). Therefore, in 
order to identify the murine counterpart to human BAPC another set of marker have 
to be determined that is characteristic for the mouse BAPC subset. Identification of 
the murine counterpart will enable more detailed studies on the molecular 
regulation of this subset. 
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